@NP	Corticospinal Axons	21
@NP	Not Cross	44
@NP	Spinal Lesion Gaps	60
@NP	a Multifactorial Transplantation	85
@NP	Olfactory Ensheathing Cell/Olfactory Nerve Fibroblast-Biomatrix Bridges R.	133
@NP	Deumens ,1 * G.C.	208
@NP	Deumens	208
@NP	,1 * G.C.	215
@NP	,1	215
@NP	G.C.	219
@NP	Koopmans ,1,2 W.M.M.	224
@NP	Koopmans ,1,2	224
@NP	W.M.M.	237
@NP	Honig ,2 V.	244
@NP	Honig ,2	244
@NP	V.	252
@NP	Maquet ,3 R.	255
@NP	Maquet ,3	255
@NP	R.	264
@NP	Je ' roˆme ,3 H.W.M.	267
@NP	Je ' roˆme ,3	267
@NP	Je ' roˆme	267
@NP	Je '	267
@NP	,3	275
@NP	H.W.M.	278
@NP	Steinbusch ,1 and E.A.J.	285
@NP	Steinbusch ,1	285
@NP	E.A.J.	302
@NP	Joosten2 1Department	309
@NP	Psychiatry and Neuropsychology	333
@NP	Division Neuroscience	365
@NP	European Graduate School of Neuroscience -LRB- EURON -RRB-	388
@NP	European Graduate School	388
@NP	Neuroscience -LRB- EURON -RRB-	416
@NP	Neuroscience	416
@NP	EURON	430
@NP	University of Maastricht	438
@NP	University	438
@NP	Maastricht	452
@NP	Maastricht	464
@NP	The Netherlands 2Department of Anesthesiology	476
@NP	The Netherlands 2Department	476
@NP	Anesthesiology	507
@NP	Academic Hospital Maastricht	523
@NP	Maastricht	553
@NP	The Netherlands 3Center for Education and Research on Macromolecules	565
@NP	The Netherlands 3Center	565
@NP	Education and Research	593
@NP	Macromolecules	619
@NP	University of Lie ` ge	635
@NP	University	635
@NP	Lie ` ge	649
@NP	Lie ` ge	657
@NP	Lie	657
@NP	ge	661
@NP	Belgium Transplantation	665
@NP	mixed cultures	694
@NP	olfactory ensheathing cell -LRB- OEC -RRB-	720
@NP	olfactory ensheathing cell	720
@NP	OEC	748
@NP	olfactory nerve fibroblasts -LRB- ONF -RRB-	757
@NP	olfactory nerve fibroblasts	757
@NP	ONF	786
@NP	regrowth of	819
@NP	regrowth	819
@NP	chronically injured corticospinal -LRB- CS -RRB- axons across small spinal cord	848
@NP	chronically injured corticospinal -LRB- CS -RRB- axons	848
@NP	CS	883
@NP	small spinal cord	900
@NP	we	937
@NP	a multifactorial transplantation strategy	945
@NP	regrowth of chronically injured CS axons	1000
@NP	regrowth	1000
@NP	chronically injured CS axons	1012
@NP	large spinal cord lesion gaps	1048
@NP	This strategy	1079
@NP	the transplantation of aligned OEC/ONF-biomatrix complexes	1102
@NP	the transplantation	1102
@NP	aligned OEC/ONF-biomatrix complexes	1125
@NP	Deumens et al. -LSB- 2004 -RSB- Neuroscience 125:591 -- 604	1187
@NP	Deumens et al. -LSB-	1187
@NP	2004 -RSB- Neuroscience 125:591 -- 604	1203
@NP	2004	1203
@NP	Neuroscience 125:591 -- 604	1209
@NP	the lesion gap with additional OEC/ONF injections rostral	1243
@NP	the lesion gap	1243
@NP	additional OEC/ONF injections rostral	1263
@NP	the lesion site	1315
@NP	We	1332
@NP	an enhanced presence of injured CS axons	1340
@NP	an enhanced presence	1340
@NP	injured CS axons	1364
@NP	the lesion gap	1401
@NP	no effects on injured CS axons	1422
@NP	no effects	1422
@NP	injured CS axons	1436
@NP	the lesion gap	1469
@NP	injured CS axons	1498
@NP	the OEC/ONFbiomatrix complex	1533
@NP	the lesion gap	1569
@NP	The enhanced presence of CS axons rostral to the lesion gap	1585
@NP	The enhanced presence	1585
@NP	CS axons rostral to the lesion gap	1610
@NP	CS axons rostral	1610
@NP	the lesion gap	1630
@NP	any recovery	1668
@NP	behavioral parameters assessed with the BBB locomotor rating scale or Cat	1684
@NP	behavioral parameters	1684
@NP	the BBB locomotor rating scale or Cat	1720
@NP	the BBB locomotor rating scale	1720
@NP	Cat	1754
@NP	gait analysis	1764
@NP	We	1779
@NP	our multifactorial transplantation strategy	1796
@NP	an OEC/ONF continuum	1870
@NP	the injured spinal cord	1894
@NP	regrowth of injured CS axons across large spinal lesion gaps	1940
@NP	regrowth	1940
@NP	injured CS axons across large spinal lesion gaps	1952
@NP	injured CS axons	1952
@NP	large spinal lesion gaps	1976
@NP	VVC 2006 Wiley-Liss , Inc. .	2002
@NP	VVC 2006	2002
@NP	Wiley-Liss , Inc.	2011
@NP	Repair strategies in experimental spinal cord injury -LRB- SCI -RRB-	2030
@NP	Repair strategies	2030
@NP	experimental spinal cord injury -LRB- SCI -RRB-	2051
@NP	experimental spinal cord injury	2051
@NP	SCI	2084
@NP	regrowth of severed axons	2121
@NP	regrowth	2121
@NP	severed axons	2133
@NP	those of the corticospinal -LRB- CS -RRB- tract	2158
@NP	those	2158
@NP	the corticospinal -LRB- CS -RRB- tract	2167
@NP	The success of many repair strategies	2197
@NP	The success	2197
@NP	many repair strategies	2212
@NP	the time	2275
@NP	injury -LRB- Houle and Tessler , 2003 -RRB-	2290
@NP	injury	2290
@NP	Houle and Tessler , 2003	2298
@NP	Houle	2298
@NP	Tessler , 2003	2308
@NP	Tessler	2308
@NP	2003	2317
@NP	This	2324
@NP	a changing environment	2346
@NP	the injured spinal cord	2372
@NP	a change in the intrinsic capacity of injured neurons to regrow	2400
@NP	a change	2400
@NP	the intrinsic capacity of injured neurons	2412
@NP	the intrinsic capacity	2412
@NP	injured neurons	2438
@NP	the initial -LRB- acute -RRB- stages after injury	2472
@NP	the initial -LRB- acute -RRB- stages	2472
@NP	injury	2505
@NP	inflammatory processes and alterations	2513
@NP	the extracellular matrix -LRB- ECM -RRB-	2555
@NP	the extracellular matrix	2555
@NP	ECM	2581
@NP	Dusart and Schwab , 1994 ; Tang et al. , 2003	2599
@NP	Dusart and Schwab	2599
@NP	1994 ; Tang et al.	2618
@NP	1994	2618
@NP	Tang et al.	2624
@NP	Tang	2624
@NP	et al.	2629
@NP	2003	2637
@NP	chronic	2651
@NP	stages	2660
@NP	fibroglial scarring	2688
@NP	the formation	2712
@NP	large cystic cavities	2729
@NP	Schwab and Bartholdi , 1996 ; Tang et al. , 2003 ; Silver and Miller , 2004	2752
@NP	Schwab and Bartholdi , 1996 ; Tang et al.	2752
@NP	Schwab and Bartholdi , 1996	2752
@NP	Schwab and Bartholdi	2752
@NP	1996	2774
@NP	Tang et al.	2780
@NP	Tang	2780
@NP	et al.	2785
@NP	2003 ; Silver	2793
@NP	2003	2793
@NP	Silver	2799
@NP	Miller , 2004	2810
@NP	Miller	2810
@NP	2004	2818
@NP	addition	2828
@NP	neurons	2846
@NP	growth-associated genes	2876
@NP	a sprouting response	2912
@NP	Skene , 1989 ; Tetzlaff et al. , 1991 ; Kost and Oblinger , 1993	2934
@NP	Skene , 1989 ; Tetzlaff et al.	2934
@NP	Skene , 1989	2934
@NP	Skene	2934
@NP	1989	2941
@NP	Tetzlaff et al.	2947
@NP	Tetzlaff	2947
@NP	et al.	2956
@NP	1991 ; Kost	2964
@NP	1991	2964
@NP	Kost	2970
@NP	Oblinger , 1993	2979
@NP	Oblinger	2979
@NP	1993	2989
@NP	time	3011
@NP	the severed neurons	3017
@NP	growth-associated genes	3051
@NP	Houle	3076
@NP	et al. , 1998 ; Houle and Tessler , 2003	3082
@NP	et al.	3082
@NP	1998 ; Houle and Tessler	3090
@NP	1998	3090
@NP	Houle and Tessler	3096
@NP	2003	3115
@NP	their axons	3133
@NP	the injury site -LRB- Pallini et al. , 1988 ; Hill et al. , 2001 -RRB-	3150
@NP	the injury site	3150
@NP	Pallini	3167
@NP	et al. , 1988 ; Hill et al. , 2001	3175
@NP	et al.	3175
@NP	1988 ; Hill et al.	3183
@NP	1988	3183
@NP	Hill et al.	3189
@NP	Hill	3189
@NP	et al.	3194
@NP	2001	3202
@NP	a process called axonal die-back	3209
@NP	a process	3209
@NP	axonal die-back	3226
@NP	Most repair strategies	3243
@NP	cell transplantation	3277
@NP	the growth-promoting properties of the injured spinal cord environment	3323
@NP	the growth-promoting properties	3323
@NP	the injured spinal cord environment	3358
@NP	the last decade	3398
@NP	transplantation of olfactory glia	3415
@NP	transplantation	3415
@NP	olfactory glia	3434
@NP	much attention	3462
@NP	the putative capacity of these cells	3488
@NP	the putative capacity	3488
@NP	these cells	3513
@NP	the injured spinal cord	3535
@NP	Transplantation	3560
@NP	mixed cultures	3579
@NP	olfactory ensheathing cells	3597
@NP	OEC	3626
@NP	olfactory nerve fibroblasts	3635
@NP	ONF	3664
@NP	regrowth of acutely injured CS axons	3684
@NP	regrowth	3684
@NP	acutely injured CS axons	3696
@NP	small spinal lesion gaps and partial functional recovery	3728
@NP	spinal lesion gaps	3734
@NP	Li	3786
@NP	et al. , 1997 , 1998 , 2003	3789
@NP	et al.	3789
@NP	1997	3797
@NP	1998	3803
@NP	2003	3809
@NP	Studies in which purified OEC cultures were used	3816
@NP	Studies	3816
@NP	purified OEC cultures	3833
@NP	similar results : regrowth of acutely injured CS axons	3872
@NP	similar results	3872
@NP	regrowth of acutely injured CS axons	3889
@NP	regrowth	3889
@NP	acutely injured CS axons	3901
@NP	small lesion gaps	3933
@NP	partial functional recovery	3955
@NP	Ramon	3984
@NP	Cueto et al. , 2000 ; Lu et al. , 2001 ; Nash et al. , 2002	3991
@NP	Cueto	3991
@NP	et al. , 2000 ; Lu et al. , 2001 ; Nash et al. , 2002	3997
@NP	et al. , 2000	3997
@NP	et al.	3997
@NP	2000	4005
@NP	Lu et al. , 2001	4011
@NP	Lu	4011
@NP	et al. , 2001	4014
@NP	et al.	4014
@NP	2001	4022
@NP	Nash et al. , 2002	4028
@NP	Nash	4028
@NP	et al. , 2002	4033
@NP	et al.	4033
@NP	2002	4041
@NP	Stimulation	4048
@NP	long-distance regrowth	4063
@NP	chronically injured CS axons	4089
@NP	clinically relevant , large spinal lesion gaps	4125
@NP	The use of mixed OEC	4197
@NP	The use	4197
@NP	mixed OEC	4208
@NP	ONF cultures	4219
@NP	this respect for two reasons	4252
@NP	this respect	4252
@NP	two reasons	4269
@NP	OEC and ONF	4289
@NP	the process	4337
@NP	long-distance axon regeneration	4352
@NP	the olfactory system -LRB- Li et al. , 2005 -RRB-	4387
@NP	the olfactory system	4387
@NP	Li	4409
@NP	et al. , 2005	4412
@NP	et al.	4412
@NP	2005	4420
@NP	regrowth of chronically injured CS axons across small spinal lesion gaps	4435
@NP	regrowth	4435
@NP	chronically injured CS axons across small spinal lesion gaps	4447
@NP	chronically injured CS axons	4447
@NP	small spinal lesion gaps	4483
@NP	transplantation	4532
@NP	mixed OEC/ONF cultures -LRB- Keyvan-Fouladi et al. , 2003 -RRB-	4551
@NP	mixed OEC/ONF cultures	4551
@NP	Keyvan-Fouladi	4575
@NP	et al. , 2003	4590
@NP	et al.	4590
@NP	2003	4598
@NP	the present study	4608
@NP	we	4627
@NP	delayed OEC/ONF transplantation into 2-mm-long dorsal hemisection lesions	4643
@NP	delayed OEC/ONF transplantation	4643
@NP	2-mm-long dorsal hemisection lesions	4680
@NP	Four weeks	4718
@NP	the time of delay	4745
@NP	the time	4745
@NP	delay	4757
@NP	this time	4772
@NP	a chronic spinal cord injury -LRB- Houle and Tessler , 2003 -RRB-	4806
@NP	spinal cord injury -LRB- Houle and Tessler , 2003 -RRB-	4816
@NP	spinal cord injury	4816
@NP	Houle and Tessler , 2003	4836
@NP	Houle	4836
@NP	Tessler , 2003	4846
@NP	Tessler	4846
@NP	2003	4855
@NP	large cavitations	4879
@NP	millions of OEC/ONF	4915
@NP	millions	4915
@NP	OEC/ONF	4927
@NP	we	4936
@NP	an aligned OEC/ONF-biomatrix complex -LRB- Deumens et al. , 2004 -RRB-	4944
@NP	an aligned OEC/ONF-biomatrix complex	4944
@NP	Deumens	4982
@NP	et al. , 2004	4990
@NP	et al.	4990
@NP	2004	4998
@NP	a continuum of OEC/ONF	5015
@NP	a continuum	5015
@NP	OEC/ONF	5030
@NP	the injured spinal cord	5044
@NP	an isolated OEC / ONF transplant within the lesion site , additional OEC /	5086
@NP	an isolated OEC	5086
@NP	ONF transplant within the lesion site , additional OEC	5103
@NP	ONF transplant	5103
@NP	the lesion site , additional OEC	5125
@NP	ONF injections	5158
@NP	the rostral and caudal host stumps	5188
@NP	the rostral	5188
@NP	caudal host stumps	5204
@NP	We	5224
@NP	our multifactorial transplantation strategy	5245
@NP	OEC/ONF-biomatrix plus OEC/ONF cell injections	5290
@NP	OEC/ONF-biomatrix	5290
@NP	OEC/ONF cell injections	5313
@NP	regrowth of injured CS axons across large lesion gaps	5349
@NP	regrowth	5349
@NP	injured CS axons across large lesion gaps	5361
@NP	injured CS axons	5361
@NP	large lesion gaps	5385
@NP	We	5404
@NP	a recovery	5430
@NP	the locomotor parameter stride length of the hind limbs	5444
@NP	the locomotor parameter stride length	5444
@NP	the hind limbs	5485
@NP	this parameter	5509
@NP	the integrity of the CS tract -LRB- Starkey et al. , 2005 -RRB-	5553
@NP	the integrity	5553
@NP	the CS tract -LRB- Starkey et al. , 2005 -RRB-	5570
@NP	the CS tract	5570
@NP	Starkey	5584
@NP	et al. , 2005	5592
@NP	et al.	5592
@NP	2005	5600
@NP	we	5615
@NP	the effects of the complete multifactorial approach	5637
@NP	the effects	5637
@NP	the complete multifactorial approach	5652
@NP	control animals	5690
@NP	culture medium injections	5720
@NP	the host stumps	5751
@NP	the injection procedure	5782
@NP	MATERIALS AND METHODS	5808
@NP	Study Design All	5830
@NP	experimental procedures	5847
@NP	the recommendations of the European Commission	5899
@NP	the recommendations	5899
@NP	the European Commission	5922
@NP	European Communities Council Directive of 24 November 1986 ; 86/609/EEC	5947
@NP	European Communities Council Directive	5947
@NP	24 November 1986 ; 86/609/EEC	5989
@NP	24 November 1986	5989
@NP	24	5989
@NP	November 1986	5992
@NP	86/609/EEC	6007
@NP	protocols	6024
@NP	the Committee	6051
@NP	Animal Research of the Maastricht University -LRB- DEC 2004 - 030 -RRB-	6068
@NP	Animal Research	6068
@NP	the Maastricht University -LRB- DEC 2004 - 030 -RRB-	6087
@NP	the Maastricht University	6087
@NP	DEC 2004 - 030	6114
@NP	DEC 2004	6114
@NP	030	6124
@NP	this study	6133
@NP	every attempt	6145
@NP	the number of animals and their suffering	6180
@NP	the number	6180
@NP	animals and their suffering	6194
@NP	animals	6194
@NP	their suffering	6206
@NP	Adult male Lewis rats	6223
@NP	inbred , animal facilities of Maastricht University	6246
@NP	inbred , animal facilities	6246
@NP	Maastricht University	6275
@NP	CatWalk gait analysis -LRB- Hamers et al. , 2001 -RRB-	6318
@NP	CatWalk gait analysis	6318
@NP	Hamers	6341
@NP	et al. , 2001	6348
@NP	et al.	6348
@NP	2001	6356
@NP	the age of 7 -- 9 weeks	6365
@NP	the age of 7	6365
@NP	the age	6365
@NP	7	6376
@NP	9 weeks	6378
@NP	the age of 9 weeks	6390
@NP	the age	6390
@NP	9 weeks	6401
@NP	the animals	6410
@NP	a dorsal hemisection injury	6440
@NP	T11/T12	6471
@NP	the following 4 weeks	6487
@NP	the animals	6510
@NP	the conventional BBB locomotor rating scale -LRB- Basso et al. , 1995 -RRB-	6558
@NP	the conventional BBB locomotor rating scale	6558
@NP	Basso	6603
@NP	et al. , 1995	6609
@NP	et al.	6609
@NP	1995	6617
@NP	the CatWalk gait analysis -LRB- Hamers et al. , 2001 -RRB-	6627
@NP	the CatWalk gait analysis	6627
@NP	Hamers	6654
@NP	et al. , 2001	6661
@NP	et al.	6661
@NP	2001	6669
@NP	4 weeks after dorsal hemisection	6679
@NP	4 weeks	6679
@NP	dorsal hemisection	6693
@NP	the animals	6713
@NP	two groups	6743
@NP	One group of animals -LRB- n = 8 -RRB-	6755
@NP	One group	6755
@NP	animals -LRB- n = 8 -RRB-	6768
@NP	animals	6768
@NP	n	6777
@NP	8	6781
@NP	a multifactorial transplantantion strategy	6809
@NP	the other group -LRB- n = 8 -RRB-	6857
@NP	the other group	6857
@NP	n	6874
@NP	8	6878
@NP	the control group -LRB- see below -RRB-	6891
@NP	the control group	6891
@NP	This transplantation strategy	6922
@NP	OEC / ONF complexes	6987
@NP	OEC	6987
@NP	ONF complexes	6992
@NP	the lesion site	7011
@NP	OEC/ONF suspensions rostral and caudal	7041
@NP	OEC/ONF suspensions	7041
@NP	the lesion site	7083
@NP	the following 12 weeks	7107
@NP	the animals	7131
@NP	the above-mentioned locomotor tests	7180
@NP	9 weeks	7220
@NP	transplantation	7234
@NP	13 weeks	7257
@NP	SCI	7272
@NP	the CS tract	7277
@NP	biodextran amine -LRB- BDA -RRB-	7324
@NP	biodextran amine	7324
@NP	BDA	7342
@NP	16 weeks after SCI	7351
@NP	16 weeks	7351
@NP	SCI	7366
@NP	the animals	7371
@NP	histological analysis	7423
@NP	the postoperative period	7457
@NP	histological analysis	7493
@NP	the researchers	7516
@NP	the treatment	7546
@NP	OEC/ONF and Biomatrix Complexes Syngeneic OEC/ONF	7561
@NP	OEC/ONF	7561
@NP	Biomatrix Complexes Syngeneic OEC/ONF	7573
@NP	Biomatrix Complexes	7573
@NP	Syngeneic OEC/ONF	7593
@NP	the outer two glomerular layers of adult Lewis rat	7630
@NP	the outer two glomerular layers	7630
@NP	adult Lewis rat	7665
@NP	olfactory bulbs	7681
@NP	methods described elsewhere -LRB- Ramon-Cueto and Nieto-Sampedro , 1992 -RRB-	7700
@NP	methods	7700
@NP	Ramon-Cueto and Nieto-Sampedro , 1992	7729
@NP	Ramon-Cueto and Nieto-Sampedro	7729
@NP	1992	7761
@NP	purification	7780
@NP	9-week-old Lewis rats , bred at the animal facilities of Maastricht University ,	7803
@NP	9-week-old Lewis rats	7803
@NP	the animal facilities of Maastricht University	7834
@NP	the animal facilities	7834
@NP	Maastricht University	7859
@NP	The olfactory bulbs	7900
@NP	meninges	7950
@NP	careful dissection of the outer two glomerular layers	7972
@NP	careful dissection	7972
@NP	the outer two glomerular layers	7994
@NP	The tissue	8027
@NP	small fragments	8053
@NP	trypsin	8088
@NP	0.1 % in phosphate-buffered saline ; Gibco	8097
@NP	0.1 %	8097
@NP	phosphate-buffered saline ; Gibco	8105
@NP	phosphate-buffered saline	8105
@NP	Gibco	8132
@NP	Invitrogen , Breda , The Netherlands	8139
@NP	Invitrogen	8139
@NP	Breda	8151
@NP	The Netherlands	8158
@NP	378C for 15 min	8178
@NP	378C	8178
@NP	15 min	8187
@NP	Trypsinization	8195
@NP	addition of culture medium	8225
@NP	addition	8225
@NP	culture medium	8237
@NP	Dulbecco 's	8253
@NP	Eagle 's medium	8273
@NP	Eagle 's	8273
@NP	DMEM/NUT mix F12 ; Gibco / Invitrogen	8289
@NP	DMEM/NUT mix F12	8289
@NP	Gibco / Invitrogen	8307
@NP	Gibco	8307
@NP	Invitrogen	8314
@NP	glutamax-I supplemented with 10 %	8331
@NP	glutamax-I	8331
@NP	10 %	8360
@NP	fetal calf serum -LRB- Bodinco , Alkmaar , The Netherlands -RRB-	8376
@NP	fetal calf serum	8376
@NP	Bodinco	8394
@NP	Alkmaar	8403
@NP	The Netherlands	8412
@NP	antibiotics -LRB- 100 U/ml penicillin and 100 µg/ml streptomycin -RRB-	8433
@NP	antibiotics	8433
@NP	100 U/ml penicillin and 100 µg/ml streptomycin	8446
@NP	100 U/ml penicillin	8446
@NP	100 µg/ml streptomycin	8470
@NP	the tissue	8501
@NP	culture medium	8534
@NP	it	8550
@NP	1 ml of culture medium	8570
@NP	1 ml	8570
@NP	culture medium	8578
@NP	Single-cell dissociation	8594
@NP	mechanical trituration	8635
@NP	The cultures that are obtained by this procedure	8659
@NP	The cultures	8659
@NP	this procedure	8693
@NP	a mixed population	8717
@NP	OEC and ONF -LRB- OEC/ONF -RRB- , as described previously	8739
@NP	OEC and ONF -LRB- OEC/ONF -RRB-	8739
@NP	OEC and ONF	8739
@NP	OEC/ONF	8752
@NP	Li	8787
@NP	et al. , 1998 , Deumens et al. , 2004	8790
@NP	et al.	8790
@NP	1998 , Deumens et al.	8798
@NP	1998	8798
@NP	Deumens et al.	8804
@NP	Deumens	8804
@NP	et al.	8812
@NP	2004	8820
@NP	The OEC/ONF cultures	8827
@NP	poly-L-lysine-coated Petri dishes	8863
@NP	a density of 200,000 cells in 2 ml of culture medium per Petri dish	8900
@NP	a density	8900
@NP	200,000 cells in 2 ml of culture medium per Petri dish	8913
@NP	200,000 cells	8913
@NP	2 ml of culture medium per Petri dish	8930
@NP	2 ml	8930
@NP	culture medium per Petri dish	8938
@NP	culture medium	8938
@NP	Petri dish	8957
@NP	The cells	8969
@NP	4	8994
@NP	5 days in vitro -LRB- DIV -RRB- before half of the culture medium	8996
@NP	5 days	8996
@NP	-LRB- DIV -RRB- before half of the culture medium	9012
@NP	-LRB- DIV -RRB-	9012
@NP	half of the culture medium	9025
@NP	half	9025
@NP	the culture medium	9033
@NP	the culture medium	9079
@NP	every 2 days	9112
@NP	DIV10	9129
@NP	a subset of the OEC/ONF cultures	9136
@NP	a subset	9136
@NP	the OEC/ONF cultures	9148
@NP	the Petri dishes	9188
@NP	them	9213
@NP	PLA/PLA-b-PEO matrices	9221
@NP	transplantation	9263
@NP	the spinal lesion site	9284
@NP	the rest of the OEC/ONF cultures	9312
@NP	the rest	9312
@NP	the OEC/ONF cultures	9324
@NP	the Petri dishes	9363
@NP	intraspinal OEC/ONF injections	9393
@NP	Collection of the OEC/ONF cultures from the Petri dishes	9425
@NP	Collection	9425
@NP	the OEC/ONF cultures from the Petri dishes	9439
@NP	the OEC/ONF cultures	9439
@NP	the Petri dishes	9465
@NP	a 5-min incubation in 0.1 %	9494
@NP	a 5-min incubation	9494
@NP	0.1 %	9516
@NP	Fluka BioChemika , Buchs , Switzerland	9543
@NP	Fluka BioChemika	9543
@NP	Buchs , Switzerland	9561
@NP	378C	9593
@NP	Trypsinization	9599
@NP	culture medium	9635
@NP	a 10-min centrifugation at 1,200 rpm	9657
@NP	a 10-min centrifugation	9657
@NP	1,200 rpm	9684
@NP	the pellet	9695
@NP	culture medium	9725
@NP	OEC/ONF cultures	9741
@NP	the surface area of the PLA/PLA-b-PEO matrices -LRB- Deumens et al. , 2004 -RRB-	9777
@NP	the surface area	9777
@NP	the PLA/PLA-b-PEO matrices -LRB- Deumens et al. , 2004 -RRB-	9797
@NP	the PLA/PLA-b-PEO matrices	9797
@NP	Deumens et al. , 2004	9825
@NP	Deumens	9825
@NP	et al.	9833
@NP	2004	9841
@NP	a density of about 40,000 cells/cm2	9850
@NP	a density	9850
@NP	40,000 cells/cm2	9869
@NP	these substrates for 4 days	9899
@NP	these substrates	9899
@NP	4 days	9920
@NP	This protocol	9928
@NP	OEC/ONF-biomatrix complexes as described previously	9958
@NP	OEC/ONF-biomatrix complexes	9958
@NP	Deumens	10011
@NP	et al. , 2004	10019
@NP	et al.	10019
@NP	2004	10027
@NP	One day before transplantation -LRB- i.e. , DIV13 -RRB- , both the OEC	10034
@NP	One day	10034
@NP	transplantation -LRB- i.e. , DIV13 -RRB- , both the OEC	10049
@NP	transplantation	10049
@NP	i.e. , DIV13	10066
@NP	i.e.	10066
@NP	DIV13	10072
@NP	the OEC	10085
@NP	ONF cultures and the OEC/ONF-biomatrix complexes	10094
@NP	ONF cultures	10094
@NP	the OEC/ONF-biomatrix complexes	10111
@NP	Hoechst	10164
@NP	This	10173
@NP	a 40 -- 60-min incubation at 37 °C in 2 µg/ml	10190
@NP	a 40	10190
@NP	60-min incubation at 37 °C in 2 µg/ml	10195
@NP	60-min incubation	10195
@NP	37 °C in 2 µg/ml	10216
@NP	37 °C	10216
@NP	2 µg/ml	10224
@NP	Hoechst 33342 -LRB- Sigma , Uithoorn , The Netherlands -RRB- in culture medium	10232
@NP	Hoechst 33342 -LRB- Sigma , Uithoorn , The Netherlands -RRB-	10232
@NP	Hoechst 33342	10232
@NP	Sigma	10247
@NP	Uithoorn	10254
@NP	The Netherlands	10264
@NP	culture medium	10284
@NP	the OEC/ONF cultures and OEC/ONF-biomatrices	10312
@NP	culture medium	10386
@NP	Surgeries General .	10402
@NP	every operation -LRB- i.e. , SCI , transplantation , and CS tract labeling -RRB-	10425
@NP	every operation	10425
@NP	i.e. , SCI , transplantation , and CS tract labeling	10442
@NP	i.e.	10442
@NP	SCI	10448
@NP	transplantation	10453
@NP	CS tract labeling	10474
@NP	animals	10494
@NP	intraperitoneal -LRB- i.p. -RRB- injections	10511
@NP	Temgesic -LRB- 0.1 ml/animal ; Schering-Plough , Utrecht , The Netherlands -RRB-	10550
@NP	Temgesic	10550
@NP	0.1 ml/animal ; Schering-Plough	10560
@NP	0.1 ml/animal	10560
@NP	Schering-Plough	10575
@NP	Utrecht , The Netherlands	10592
@NP	Utrecht	10592
@NP	The Netherlands	10601
@NP	One hour	10619
@NP	the injection	10634
@NP	the animals	10649
@NP	a mixture of 1	10684
@NP	a mixture	10684
@NP	1	10697
@NP	2 % halothane -LRB- Abbott , Hoofddorp , The Netherlands -RRB-	10699
@NP	2 % halothane	10699
@NP	Abbott	10713
@NP	Hoofddorp	10721
@NP	The Netherlands	10732
@NP	O2/N2O -LRB- 1:2 -RRB-	10753
@NP	O2/N2O	10753
@NP	1:2	10761
@NP	an ophthalmic ointment	10771
@NP	Visagel -LRB- Eurovet , Bladel , The Netherlands -RRB-	10795
@NP	Visagel	10795
@NP	Eurovet	10804
@NP	Bladel	10813
@NP	The Netherlands	10821
@NP	the eyes	10854
@NP	the operation	10888
@NP	the beginning of every operation	10906
@NP	the beginning	10906
@NP	every operation	10923
@NP	the hair overlying the operation area	10940
@NP	the hair	10940
@NP	the operation area	10959
@NP	the skin	10993
@NP	Betadine	11016
@NP	the end of every operation	11029
@NP	the end	11029
@NP	every operation	11040
@NP	the muscles and skin	11057
@NP	animals	11095
@NP	awake	11123
@NP	their home cages	11150
@NP	At least 1 hr	11168
@NP	their awakening	11188
@NP	the animals	11205
@NP	another i.p. injection	11226
@NP	Temgesic	11254
@NP	SCI	11264
@NP	the age of 9 weeks	11272
@NP	the age	11272
@NP	9 weeks	11283
@NP	a laminectomy	11292
@NP	T11/T12 of 16 animals	11323
@NP	T11/T12	11323
@NP	16 animals	11334
@NP	the spinal cord	11349
@NP	The dura mater	11378
@NP	the use of microscissors	11411
@NP	the use	11411
@NP	microscissors	11422
@NP	the dorsal half of the spinal cord	11436
@NP	the dorsal half	11436
@NP	the spinal cord	11455
@NP	two spinal levels	11486
@NP	2 mm	11505
@NP	an aspiration device	11526
@NP	the dorsal part of the spinal cord between the two cuts	11548
@NP	the dorsal part	11548
@NP	the spinal cord between the two cuts	11567
@NP	the spinal cord	11567
@NP	the two cuts	11591
@NP	Standardization of the lesion depth -LRB- 1.2 mm -RRB-	11617
@NP	Standardization of the lesion depth	11617
@NP	Standardization	11617
@NP	the lesion depth	11636
@NP	1.2 mm	11654
@NP	the dorsal part of the CS tract	11684
@NP	the dorsal part	11684
@NP	the CS tract	11703
@NP	a reference	11719
@NP	The dorsal CS tract	11732
@NP	the ventralmost part of the dorsal funiculus	11766
@NP	the ventralmost part	11766
@NP	the dorsal funiculus	11790
@NP	removal of the dorsal CS tract	11822
@NP	removal	11822
@NP	the dorsal CS tract	11833
@NP	the central canal and central gray matter	11854
@NP	the central canal	11854
@NP	central gray matter	11876
@NP	the center of the spinal cord	11915
@NP	the center	11915
@NP	the spinal cord	11929
@NP	this	11952
@NP	the lesion	11958
@NP	This lesion	11993
@NP	descending rubrospinal axons	12016
@NP	the dorsal component of the CS tract	12046
@NP	the dorsal component	12046
@NP	the CS tract	12070
@NP	all ascending dorsal column axons	12084
@NP	all	12084
@NP	dorsal column axons	12098
@NP	local spinal sensory neurites	12123
@NP	Four weeks	12171
@NP	SCI	12188
@NP	the spinal lesion site	12193
@NP	the connective tissue that massively invaded the lesion site	12252
@NP	the connective tissue	12252
@NP	the lesion site	12297
@NP	The experimental group of eight animals	12314
@NP	The experimental group	12314
@NP	eight animals	12340
@NP	an OEC/ONF-biomatrix transplant	12363
@NP	the thoracic lesion site , which was then covered with DuraFilm	12400
@NP	the thoracic lesion site	12400
@NP	DuraFilm	12454
@NP	addition	12467
@NP	OEC/ONF suspensions	12477
@NP	100,000 cells/ll ; 2 ll per injection site ; one injection site/stump	12498
@NP	100,000 cells/ll	12498
@NP	2 ll per injection site ; one injection site/stump	12516
@NP	2 ll per injection site	12516
@NP	2 ll	12516
@NP	injection site	12525
@NP	one injection site/stump	12541
@NP	the rostral and caudal cord stumps	12586
@NP	the rostral	12586
@NP	caudal cord stumps	12602
@NP	a distance of 1 mm	12624
@NP	a distance	12624
@NP	1 mm	12638
@NP	the lesion site	12648
@NP	a depth of 1.2 mm	12671
@NP	a depth	12671
@NP	1.2 mm	12682
@NP	The control group of eight animals	12690
@NP	The control group	12690
@NP	eight animals	12711
@NP	culture medium injections	12739
@NP	1 mm	12765
@NP	rostral and caudal	12770
@NP	the lesion site	12792
@NP	possible damage induced by the injection procedure	12823
@NP	possible damage	12823
@NP	the injection procedure	12850
@NP	CS tract	12875
@NP	A dental drill	12894
@NP	burr holes	12926
@NP	both sides of the cranium overlying the sensorimotor cortices	12940
@NP	both sides	12940
@NP	the cranium overlying the sensorimotor cortices	12954
@NP	the cranium	12954
@NP	the sensorimotor cortices	12976
@NP	The anterograde neuronal tracer biotin dextran amine	13003
@NP	BDA	13057
@NP	MW 10,000 ; Molecular Probes/Invitrogen	13062
@NP	MW 10,000	13062
@NP	Molecular Probes/Invitrogen	13073
@NP	the sensorimotor cortex	13127
@NP	a depth of 2 mm	13154
@NP	a depth	13154
@NP	2 mm	13165
@NP	the cortical surface on both sides	13175
@NP	the cortical surface	13175
@NP	both sides	13199
@NP	10 %	13211
@NP	0.1 M	13218
@NP	phosphate-buffered saline	13224
@NP	PBS	13251
@NP	pH 7.2 ; 1.5 ll/three injections/hemisphere -RSB-	13257
@NP	pH 7.2	13257
@NP	1.5 ll/three injections/hemisphere -RSB-	13265
@NP	The needle	13302
@NP	place for 1 min	13325
@NP	place	13325
@NP	1 min	13335
@NP	Histology	13375
@NP	16 weeks	13388
@NP	SCI	13403
@NP	the rats	13408
@NP	an overdose of Nembutal -LRB- 30 mg/kg body weight ; i.p. injection -RRB-	13426
@NP	an overdose	13426
@NP	Nembutal -LRB- 30 mg/kg body weight ; i.p. injection -RRB-	13441
@NP	Nembutal	13441
@NP	30 mg/kg body weight	13451
@NP	injection	13478
@NP	They	13490
@NP	ice-cold 4 % paraformaldehyde in 0.1 M phosphate buffer -LRB- pH 7.4 -RRB-	13529
@NP	ice-cold 4 % paraformaldehyde	13529
@NP	0.1 M phosphate buffer -LRB- pH 7.4 -RRB-	13561
@NP	0.1 M phosphate buffer	13561
@NP	pH 7.4	13585
@NP	perfusion	13600
@NP	the spinal cords and the brains	13611
@NP	the spinal cords	13611
@NP	the brains	13632
@NP	cold 4 % buffered paraformaldehyde overnight	13673
@NP	cold	13673
@NP	paraformaldehyde overnight	13690
@NP	the following day	13721
@NP	the tissue	13740
@NP	10 % sucrose in PBS -LRB- 0.1 M , pH 7.6 -RRB-	13770
@NP	10 % sucrose	13770
@NP	PBS -LRB- 0.1 M , pH 7.6 -RRB-	13785
@NP	PBS	13785
@NP	0.1 M	13790
@NP	pH 7.6	13797
@NP	overnight	13814
@NP	48C	13827
@NP	the tissue	13838
@NP	25 % sucrose in PBS	13869
@NP	25 % sucrose	13869
@NP	PBS	13884
@NP	3 days	13901
@NP	48C	13911
@NP	The brain and 2.5-cm-long spinal cord pieces including the lesion site	13916
@NP	The brain and 2.5-cm-long spinal cord pieces	13916
@NP	the lesion site	13971
@NP	808C	14014
@NP	a cryostat	14025
@NP	the spinal cord pieces	14037
@NP	sagittal sections of 25 lm	14079
@NP	sagittal sections	14079
@NP	25 lm	14100
@NP	this way	14111
@NP	about 120 sections	14121
@NP	120 sections	14127
@NP	spinal cord	14158
@NP	The sections	14171
@NP	gelatin chrome-alumn -LRB- Sigma -RRB- - coated glass slides	14212
@NP	gelatin chrome-alumn	14212
@NP	Sigma	14234
@NP	coated glass slides	14241
@NP	20 °C	14276
@NP	Alternate sections	14282
@NP	immunohistochemistry with the following antibodies	14320
@NP	immunohistochemistry	14320
@NP	the following antibodies	14346
@NP	rabbit anti-GFAP -LRB- 1:1,000 ; Dako -RRB-	14372
@NP	rabbit anti-GFAP	14372
@NP	1:1,000 ; Dako	14390
@NP	1:1,000	14390
@NP	Dako	14399
@NP	rabbit anti-GAP43 / B50	14409
@NP	rabbit anti-GAP43	14409
@NP	B50	14427
@NP	1:2,000 ; generous gift from Leo van Halewijn	14432
@NP	1:2,000	14432
@NP	generous gift from Leo van Halewijn	14441
@NP	generous gift	14441
@NP	Leo van Halewijn	14460
@NP	Utrecht University , The Netherlands	14478
@NP	Utrecht University	14478
@NP	The Netherlands	14498
@NP	Secondary antibodies used	14516
@NP	Secondary antibodies	14516
@NP	streptavidin-Cy3	14547
@NP	1:2,000	14565
@NP	the BDA-labeled CS axons	14578
@NP	Jackson Immunoresearch Europe Ltd. , Cambridgeshire , United Kingdom	14604
@NP	Jackson Immunoresearch Europe Ltd.	14604
@NP	Cambridgeshire , United Kingdom	14640
@NP	Alexa 488-conjugated goat anti-rabbit	14676
@NP	1:100 ; Molecular Probes/Invitrogen	14715
@NP	1:100	14715
@NP	Molecular Probes/Invitrogen	14722
@NP	Antibodies	14752
@NP	0.3 % Triton X-100 in Tris-buffered saline -LRB- TBS-T -RRB-	14779
@NP	0.3 % Triton X-100	14779
@NP	Tris-buffered saline -LRB- TBS-T -RRB-	14800
@NP	Tris-buffered saline	14800
@NP	TBS-T	14822
@NP	Primary antibody incubations	14830
@NP	overnight at room temperature	14864
@NP	overnight	14864
@NP	room temperature	14877
@NP	Scondary antibody incubations	14895
@NP	1.5 hr at room temperature	14934
@NP	1.5 hr	14934
@NP	room temperature	14944
@NP	double-staining protocols	14965
@NP	the primary antibodies	14992
@NP	a mixture	15028
@NP	the incubation with the Cy-3-labeled secondary antibody	15043
@NP	the incubation	15043
@NP	the Cy-3-labeled secondary antibody	15063
@NP	the incubation	15115
@NP	the Alexa-labeled secondary antibody	15135
@NP	all antibody incubations	15180
@NP	the washing steps	15206
@NP	10 min TBS-T	15237
@NP	10 min TBS	15251
@NP	TBS-T without Triton X-100	15263
@NP	TBS-T	15263
@NP	Triton X-100	15277
@NP	10 min TBST	15296
@NP	All other washing steps	15309
@NP	All other	15309
@NP	steps	15327
@NP	3 3	15342
@NP	10 min	15346
@NP	TBS	15356
@NP	Every sixth section	15361
@NP	GFAP/BDA labeled CS axons or GAP43/BDA labeled CS axons	15404
@NP	GFAP/BDA	15404
@NP	CS axons or GAP43/BDA labeled CS axons	15421
@NP	CS axons	15421
@NP	GAP43/BDA labeled CS axons	15433
@NP	GAP43/BDA	15433
@NP	CS axons	15451
@NP	Stained sections	15461
@NP	an Olympus AX-70 microscope and epifluorescent illumination	15497
@NP	The microscope	15558
@NP	a 320 objective and a 310 projection lens	15591
@NP	a 320 objective	15591
@NP	a 310 projection lens	15611
@NP	The signal for Alexa 488 -LRB- green -RRB-	15634
@NP	The signal for Alexa 488	15634
@NP	The signal	15634
@NP	Alexa 488	15649
@NP	a narrow-band MNIBA-type FITC filter	15689
@NP	Chroma Technology Corp	15727
@NP	Rockingham	15751
@NP	VT	15763
@NP	the signal for Cy3 -LRB- red -RRB-	15768
@NP	the signal	15768
@NP	Cy3 -LRB- red -RRB-	15783
@NP	Cy3	15783
@NP	red	15788
@NP	an MNG filter -LRB- Chroma Technology Corp. -RRB-	15815
@NP	an MNG filter	15815
@NP	Chroma Technology Corp.	15830
@NP	the signal for Hoechst -LRB- blue -RRB-	15860
@NP	the signal for Hoechst	15860
@NP	the signal	15860
@NP	Hoechst	15875
@NP	a U-MNIBA filter -LRB- Chroma Technology Corp. -RRB-	15912
@NP	a U-MNIBA filter	15912
@NP	Chroma Technology Corp.	15930
@NP	Pictures	15956
@NP	the	15968
@NP	sections	15980
@NP	a magnification of 320	16002
@NP	a magnification	16002
@NP	320	16021
@NP	a Sony Power HAD 3CCD Color Video Camera or an Olympus F-view	16030
@NP	a Sony Power HAD 3CCD Color Video Camera	16030
@NP	an Olympus F-view	16074
@NP	CCD camera -LRB- Paes , Zoeterwoude , The Netherlands -RRB-	16099
@NP	CCD camera	16099
@NP	Paes	16111
@NP	Zoeterwoude	16117
@NP	The Netherlands	16130
@NP	All pictures	16148
@NP	the image analyzing system analySIS 3.0	16180
@NP	the image	16180
@NP	system analySIS 3.0	16200
@NP	-LRB- Soft Imaging System , Mu ¨ nster , Germany -RRB- .	16221
@NP	Soft	16222
@NP	System , Mu	16235
@NP	System	16235
@NP	Mu	16243
@NP	¨ nster , Germany	16245
@NP	¨ nster	16245
@NP	Germany	16253
@NP	Quantitative Analysis of CS Axons All sections with BDA-labeled CS axons	16263
@NP	Quantitative Analysis	16263
@NP	CS Axons All sections with BDA-labeled CS axons	16288
@NP	CS Axons All sections	16288
@NP	BDA-labeled CS axons	16315
@NP	quantitative analysis	16355
@NP	250-µm-wide boxes	16378
@NP	four different locations in the spinal cord sections	16411
@NP	four different locations	16411
@NP	the spinal cord sections	16439
@NP	The first box	16465
@NP	the dorsal gray/white matter at 2.5 -- 3.0 mm rostral to the injury site	16493
@NP	the dorsal gray/white matter at 2.5	16493
@NP	the dorsal gray/white matter	16493
@NP	2.5	16525
@NP	3.0 mm rostral to the injury site	16529
@NP	3.0 mm rostral	16529
@NP	the injury site	16547
@NP	the rostral reference	16582
@NP	The second box	16605
@NP	the dorsal gray/white matter directly rostral	16634
@NP	the dorsal gray/white matter	16634
@NP	the injury site	16683
@NP	The third box	16700
@NP	the gray matter	16728
@NP	the lesion site	16752
@NP	only few axons	16777
@NP	the lesion site	16816
@NP	the box	16833
@NP	the area where most BDA immunoreactivity was found	16855
@NP	the area	16855
@NP	most BDA immunoreactivity	16870
@NP	The fourth box	16907
@NP	the gray matter caudal	16936
@NP	the injury site	16962
@NP	the position where most BDA immunoreactivity could be found	16988
@NP	the position	16988
@NP	most BDA immunoreactivity	17007
@NP	The few BDA-immunoreactive CS axons	17049
@NP	the caudal gray matter within 10 mm	17117
@NP	the caudal gray matter	17117
@NP	10 mm	17147
@NP	the caudal edge of the lesion site	17158
@NP	the caudal edge	17158
@NP	the lesion site	17177
@NP	All four boxes	17194
@NP	all the sections containing BDA-labeled CS axons	17226
@NP	all the sections	17226
@NP	BDA-labeled CS axons	17254
@NP	The percentage	17276
@NP	each box	17294
@NP	BDA-immunoreactive axons -LRB- `` BDA immunoreactivity occupation '' -RRB-	17315
@NP	BDA-immunoreactive axons	17315
@NP	BDA	17343
@NP	immunoreactivity occupation ''	17347
@NP	immunoreactivity	17347
@NP	occupation ''	17364
@NP	the box values in all the sections	17396
@NP	the box values	17396
@NP	all the sections	17414
@NP	the efficiency of BDA CS tract tracing	17452
@NP	the efficiency	17452
@NP	BDA CS tract tracing	17470
@NP	BDA CS tract	17470
@NP	animals	17517
@NP	the BDA immunoreactivity at the rostral reference	17526
@NP	the BDA immunoreactivity	17526
@NP	the rostral reference	17554
@NP	the 100 % reference value of BDA-labeled axons of each animal	17589
@NP	the 100 % reference value	17589
@NP	BDA-labeled axons of each animal	17617
@NP	BDA-labeled axons	17617
@NP	each animal	17638
@NP	The BDA immunoreactivity values of boxes 2 , 3 , and 4	17651
@NP	The BDA immunoreactivity values	17651
@NP	boxes 2 , 3 , and 4	17686
@NP	boxes	17686
@NP	2 , 3 , and 4	17692
@NP	that of the rostral reference	17731
@NP	that	17731
@NP	the rostral reference	17739
@NP	A similar quantification method	17762
@NP	others -LRB- Goldshmit et al. , 2004 -RRB-	17827
@NP	others	17827
@NP	Goldshmit	17835
@NP	et al. , 2004	17845
@NP	et al.	17845
@NP	2004	17853
@NP	Functional	17860
@NP	Basso Beattie Bresnahan -LRB- BBB -RRB-	17879
@NP	Basso Beattie Bresnahan	17879
@NP	BBB	17904
@NP	locomotor rating scale	17909
@NP	This locomotor test	17933
@NP	locomotor performance of the hind limbs	17962
@NP	locomotor performance	17962
@NP	the hind limbs	17987
@NP	a score that ranges from 0 to 21 -LRB- Basso et al. , 1995 -RRB-	18026
@NP	a score	18026
@NP	0 to 21	18051
@NP	Basso	18060
@NP	et al. , 1995	18066
@NP	et al.	18066
@NP	1995	18074
@NP	The scores of the left and right hind limbs	18081
@NP	The scores	18081
@NP	the left and right hind limbs	18095
@NP	the BBB score of the animal	18152
@NP	the BBB score	18152
@NP	the animal	18169
@NP	The BBB test	18181
@NP	the day of the operation	18226
@NP	the day	18226
@NP	the operation	18237
@NP	the following days postoperatively -LRB- DPO -RRB- : 1 , 2 , 3 , 7 , and weekly	18258
@NP	the following days postoperatively -LRB- DPO -RRB-	18258
@NP	the following days postoperatively	18258
@NP	the following days	18258
@NP	DPO	18294
@NP	1 , 2 , 3 , 7 , and weekly	18300
@NP	1	18300
@NP	2	18303
@NP	3	18306
@NP	7	18309
@NP	weekly	18316
@NP	CatWalk gait analysis .	18335
@NP	CatWalk	18335
@NP	gait analysis	18343
@NP	This locomotor test	18358
@NP	an easy and objective analysis	18385
@NP	both static and dynamic locomotor parameters	18419
@NP	static	18424
@NP	dynamic locomotor parameters	18435
@NP	stride length	18473
@NP	base of support	18488
@NP	base	18488
@NP	support	18496
@NP	interlimb coordination	18505
@NP	swing/stance phases	18533
@NP	Details on the CatWalk set-up	18554
@NP	Details	18554
@NP	the CatWalk set-up	18565
@NP	Hamers et al. , 2001 ; Koopmans et al. , 2005	18608
@NP	Hamers	18608
@NP	et al. , 2001 ; Koopmans et al. , 2005	18615
@NP	et al. , 2001	18615
@NP	et al.	18615
@NP	2001	18623
@NP	Koopmans et al. , 2005	18629
@NP	Koopmans	18629
@NP	et al. , 2005	18638
@NP	et al.	18638
@NP	2005	18646
@NP	a training period of 2 weeks	18662
@NP	a training period	18662
@NP	2 weeks	18683
@NP	animals	18704
@NP	a glass runway	18721
@NP	hesitation	18744
@NP	this training period	18763
@NP	the animals	18785
@NP	a 12 g/day food-restriction protocol	18816
@NP	24 hr before postoperative testing	18857
@NP	24 hr	18857
@NP	postoperative testing	18870
@NP	the animals	18893
@NP	food	18922
@NP	Small food pellets	18928
@NP	Noyes Precision	18948
@NP	PJPPP-0045 ; Sandown Chemical Ltd. , Hampton , United Kingdom	18972
@NP	PJPPP-0045	18972
@NP	Sandown Chemical Ltd. , Hampton , United Kingdom	18984
@NP	located at the end of the glass runway	19032
@NP	the end of the glass	19043
@NP	the end	19043
@NP	the glass	19054
@NP	a reward	19084
@NP	analysis	19098
@NP	three uninterrupted runs	19108
@NP	CatWalk-based BBB scale .	19144
@NP	CatWalk-based BBB	19144
@NP	scale	19162
@NP	Forelimb-hindlimb coordination	19169
@NP	an extremely important aspect in the BBB score	19203
@NP	an extremely important aspect	19203
@NP	the BBB score	19236
@NP	the assessment of such coordination via the BBB locomotor rating scale	19260
@NP	the assessment	19260
@NP	such coordination via the BBB locomotor rating scale	19278
@NP	such coordination	19278
@NP	the BBB locomotor rating scale	19300
@NP	Correct assessment of locomotor performance	19353
@NP	Correct assessment	19353
@NP	locomotor performance	19375
@NP	correct assessment of coordination	19406
@NP	correct assessment	19406
@NP	coordination	19428
@NP	this end	19445
@NP	we	19455
@NP	a method	19484
@NP	the objective parameter	19502
@NP	coordination	19530
@NP	the regularity index -LRB- RI -RRB-	19544
@NP	the regularity index	19544
@NP	RI	19566
@NP	the CatWalk analysis	19585
@NP	the BBB	19624
@NP	scoring -LRB- Koopmans et al. , 2005 -RRB-	19632
@NP	scoring	19632
@NP	Koopmans	19641
@NP	et al. , 2005	19650
@NP	et al.	19650
@NP	2005	19658
@NP	brief	19668
@NP	the RI	19675
@NP	grades	19682
@NP	the degree of coordination as the number of normal step sequence patterns	19689
@NP	the degree	19689
@NP	coordination as the number of normal step sequence patterns	19703
@NP	coordination	19703
@NP	the number of normal step sequence patterns	19719
@NP	the number	19719
@NP	normal step sequence patterns	19733
@NP	four	19777
@NP	the total number of paw placements	19794
@NP	the total number	19794
@NP	paw placements	19814
@NP	100 %	19847
@NP	Crossings of the glass runway with a RI of 100 %	19853
@NP	Crossings	19853
@NP	the glass runway with a RI of 100 %	19866
@NP	the glass runway	19866
@NP	a RI of 100 %	19888
@NP	a RI	19888
@NP	100 %	19896
@NP	three , two , one , or none of the CatWalk runs	19932
@NP	three	19932
@NP	two	19939
@NP	one	19944
@NP	none of the CatWalk runs	19952
@NP	none	19952
@NP	the CatWalk runs	19960
@NP	no coordination	20031
@NP	the BBB score of the animal at that testing day	20072
@NP	the BBB score	20072
@NP	the animal at that testing day	20089
@NP	the animal	20089
@NP	that testing day	20103
@NP	RESULTS Figure 1 .	20136
@NP	RESULTS	20136
@NP	Figure 1	20144
@NP	Neuropathological effects of the multifactorial transplantation strategy .	20154
@NP	Neuropathological effects	20154
@NP	the multifactorial transplantation strategy	20183
@NP	Corticospinal -LRB- CS -RRB- axons	20228
@NP	a low-thoracic dorsal hemisection injury	20265
@NP	the anterograde tracer BDA	20325
@NP	These axons	20353
@NP	an unbranched course at 2.5 -- 3 mm rostral to the lesion gap -LRB- A -RRB-	20386
@NP	an unbranched course at 2.5	20386
@NP	an unbranched course	20386
@NP	2.5	20410
@NP	3 mm rostral to the lesion gap -LRB- A -RRB-	20414
@NP	3 mm rostral	20414
@NP	the lesion gap -LRB- A -RRB-	20430
@NP	the lesion gap	20430
@NP	A	20446
@NP	a sproutinglike morphology directly rostral to the lesion gap -LRB- B -RRB-	20463
@NP	a sproutinglike morphology	20463
@NP	the lesion gap	20510
@NP	B	20526
@NP	Quantitative analysis using four boxes as indicated in C	20530
@NP	Quantitative analysis	20530
@NP	four boxes	20558
@NP	indicated in C	20572
@NP	indicated	20572
@NP	C	20585
@NP	BDA immunoreactivity	20599
@NP	rostral	20650
@NP	the injury site in transplanted vs. control animals -LRB- D -RRB-	20661
@NP	the injury site	20661
@NP	transplanted vs. control animals -LRB- D -RRB-	20680
@NP	transplanted	20680
@NP	control animals -LRB- D -RRB-	20697
@NP	control animals	20697
@NP	D	20714
@NP	E	20718
@NP	These rostral CS	20721
@NP	axons -LRB- some indicated with arrowheads -RRB-	20738
@NP	axons	20738
@NP	some indicated with arrowheads	20745
@NP	some	20745
@NP	arrowheads	20765
@NP	GAP43/B50 immunoreactive -LRB- BDA in red , GAP43/B50 in green -RRB-	20786
@NP	GAP43/B50	20786
@NP	BDA in red , GAP43/B50 in green	20812
@NP	BDA	20812
@NP	red , GAP43/B50 in green	20819
@NP	red	20819
@NP	GAP43/B50 in green	20824
@NP	GAP43/B50	20824
@NP	the GAP43/B50 immunoreactive fiber -LRB- arrow -RRB-	20850
@NP	the GAP43/B50 immunoreactive fiber	20850
@NP	arrow	20886
@NP	The transplanted OEC/ONF-biomatrix within the lesion gap	20894
@NP	The transplanted OEC/ONF-biomatrix	20894
@NP	the lesion gap	20936
@NP	GAP43/B50-immunoreactive fibers -LRB- F -RRB-	20969
@NP	GAP43/B50-immunoreactive fibers	20969
@NP	F	21002
@NP	P < 0.01 .	21008
@NP	P	21008
@NP	< 0.01 .	21010
@NP	<	21010
@NP	0.01 .	21012
@NP	Figure 2 .	21019
@NP	Figure	21019
@NP	2	21026
@NP	Outcome of multifactorial transplantation strategy on gross locomotor function .	21029
@NP	Outcome	21029
@NP	multifactorial transplantation strategy	21040
@NP	gross locomotor function	21083
@NP	A : Both transplanted -LRB- OEC/ONF -RRB- and control animals	21109
@NP	: Both transplanted -LRB- OEC/ONF -RRB- and control animals	21110
@NP	Both	21112
@NP	-LRB- OEC/ONF -RRB- and control animals	21130
@NP	-LRB- OEC/ONF -RRB-	21130
@NP	control animals	21144
@NP	the BBB locomotor rating scale	21184
@NP	an initial drop in the BBB scale	21222
@NP	an initial drop	21222
@NP	the BBB scale	21241
@NP	all animals	21256
@NP	a plateau level	21281
@NP	BBB score 11 after the first postoperative week	21306
@NP	BBB score 11	21306
@NP	the first postoperative week	21325
@NP	a slight drop in the BBB	21366
@NP	a slight drop	21366
@NP	the BBB	21383
@NP	the second operation -LRB- transplantation -RRB- at DPO28 , both animal groups	21406
@NP	the second operation -LRB- transplantation -RRB-	21406
@NP	the second operation	21406
@NP	transplantation	21428
@NP	DPO28 , both animal groups	21448
@NP	DPO28	21448
@NP	animal groups	21460
@NP	this postoperative plateau	21486
@NP	B : Implementation of the CatWalk-derived regularity index	21514
@NP	B	21514
@NP	Implementation of the CatWalk-derived regularity index	21517
@NP	Implementation	21517
@NP	the CatWalk-derived regularity index	21535
@NP	RI	21573
@NP	the BBB	21582
@NP	the BBB scores	21609
@NP	no intergroup differences	21640
@NP	line	21688
@NP	the time of transplantation ; DPO , postoperative days	21704
@NP	the time of transplantation	21704
@NP	the time	21704
@NP	transplantation	21716
@NP	DPO , postoperative days	21733
@NP	DPO	21733
@NP	postoperative days	21738
@NP	Figure 3 .	21759
@NP	Figure	21759
@NP	3	21766
@NP	Outcome of multifactorial transplantation strategy on fine locomotor function .	21769
@NP	Outcome	21769
@NP	multifactorial transplantation strategy	21780
@NP	fine locomotor function	21823
@NP	Three parameters	21848
@NP	fine locomotor functions	21876
@NP	the CatWalk gait analysis	21918
@NP	The base of support -LRB- BOS -RRB- of the hind limbs	21959
@NP	The base	21959
@NP	support -LRB- BOS -RRB- of the hind limbs	21971
@NP	support -LRB- BOS -RRB-	21971
@NP	support	21971
@NP	BOS	21980
@NP	the hind limbs	21988
@NP	SCI -LRB- A -RRB-	22019
@NP	SCI	22019
@NP	A	22024
@NP	Our transplantation strategy	22028
@NP	any recovery of this parameter	22075
@NP	any recovery	22075
@NP	this parameter	22091
@NP	Both	22107
@NP	speed and stride length of the hind limbs -LRB- B , C -RRB-	22118
@NP	speed and stride length	22118
@NP	the hind limbs -LRB- B , C -RRB-	22145
@NP	the hind limbs	22145
@NP	B , C	22161
@NP	B	22161
@NP	C	22163
@NP	the SCI	22189
@NP	line	22205
@NP	the time of transplantation	22221
@NP	the time	22221
@NP	transplantation	22233
@NP	DPO	22250
@NP	all 16 animals	22279
@NP	a significant drop	22301
@NP	the BBB score	22323
@NP	postoperative time points	22340
@NP	the BBB score of all animals	22367
@NP	the BBB score	22367
@NP	all animals	22384
@NP	11 at DPO28 -LRB- the day of transplantation -RRB-	22400
@NP	11	22400
@NP	DPO28 -LRB- the day of transplantation -RRB-	22406
@NP	DPO28	22406
@NP	the day of transplantation	22413
@NP	the day	22413
@NP	transplantation	22424
@NP	This	22442
@NP	line with previous work -LRB- Joosten et al. , 2004 -RRB-	22454
@NP	line	22454
@NP	previous work -LRB- Joosten et al. , 2004 -RRB-	22464
@NP	previous work	22464
@NP	Joosten	22479
@NP	et al. , 2004	22487
@NP	et al.	22487
@NP	2004	22495
@NP	animals within these limits	22516
@NP	animals	22516
@NP	these limits	22531
@NP	1 -RRB- received a correct and standardized dorsal hemisection injury and 2	22544
@NP	1 -RRB- received a correct and standardized dorsal hemisection injury	22544
@NP	the CatWalk analysis at DPO28	22631
@NP	the CatWalk analysis	22631
@NP	DPO28	22655
@NP	These animals	22662
@NP	two groups	22715
@NP	a group	22727
@NP	a multifactorial OEC / ONF transplantation strategy and a control group	22748
@NP	a multifactorial OEC	22748
@NP	ONF transplantation strategy and a control group	22770
@NP	ONF transplantation strategy	22770
@NP	a control group	22803
@NP	Two control animals	22820
@NP	a BBB score	22844
@NP	11 at the last time point -LRB- DPO112 -RRB- , making them unsuitable	22862
@NP	11	22862
@NP	the last time point -LRB- DPO112 -RRB-	22868
@NP	the last time point	22868
@NP	DPO112	22889
@NP	them	22905
@NP	CatWalk analysis	22925
@NP	the study	22976
@NP	addition	22990
@NP	two transplanted animals	23003
@NP	no Hoechst-prelabeled cells	23029
@NP	these two animals	23096
@NP	the study	23133
@NP	the transplanted group	23151
@NP	eight animals ; the control group of six	23187
@NP	eight animals	23187
@NP	the control group of six	23202
@NP	the control group	23202
@NP	six	23223
@NP	The OEC/ONF culturing	23228
@NP	initial culturing techniques	23262
@NP	Ramon-Cueto and coworkers -LRB- 1992 -RRB-	23304
@NP	Ramon-Cueto	23304
@NP	coworkers -LRB- 1992 -RRB-	23320
@NP	coworkers	23320
@NP	1992	23331
@NP	Li	23361
@NP	et al. , 1998	23364
@NP	et al.	23364
@NP	1998	23372
@NP	Two main cell populations	23379
@NP	these cultures : the so-called OEC and ONF -LRB- Li et al. , 1998 -RRB-	23424
@NP	these cultures	23424
@NP	the so-called OEC and ONF	23440
@NP	Li	23467
@NP	et al. , 1998	23470
@NP	et al.	23470
@NP	1998	23478
@NP	The OEC population	23485
@NP	spindle-shaped cells	23530
@NP	the p75-NGF receptor	23571
@NP	S100b	23593
@NP	glial fibrillary acidic protein	23604
@NP	GFAP ; Franceschini and Barnett , 1996 ; Deumens et al. , 2004	23637
@NP	GFAP	23637
@NP	Franceschini and Barnett , 1996 ; Deumens et al. , 2004	23643
@NP	Franceschini and Barnett , 1996	23643
@NP	Franceschini and Barnett	23643
@NP	1996	23669
@NP	Deumens et al. , 2004	23675
@NP	Deumens	23675
@NP	et al. , 2004	23683
@NP	et al.	23683
@NP	2004	23691
@NP	The ONF population	23698
@NP	fibroblast-like cells	23738
@NP	proteins	23780
@NP	fibronectin and GFAP -LRB- Li et al. , 1998 ; Deumens et al. , 2004 -RRB-	23797
@NP	fibronectin and GFAP	23797
@NP	Li	23819
@NP	et al. , 1998 ; Deumens et al. , 2004	23822
@NP	et al.	23822
@NP	1998 ; Deumens et al.	23830
@NP	1998	23830
@NP	Deumens et al.	23836
@NP	Deumens	23836
@NP	et al.	23844
@NP	2004	23852
@NP	These OEC/ONF	23859
@NP	poly -LRB- D , L -RRB- - lactide matrices	23898
@NP	poly -LRB- D , L -RRB-	23898
@NP	poly	23898
@NP	lactide matrices	23908
@NP	Deumens et al. , 2004	23926
@NP	Deumens	23926
@NP	et al.	23934
@NP	2004	23942
@NP	Petri dishes	23959
@NP	Hoechst	24007
@NP	transplantation	24022
@NP	the injured spinal cord	24043
@NP	detectable by a clear blue nuclear staining of these cells	24070
@NP	a clear blue nuclear staining of these	24084
@NP	a clear blue nuclear staining	24084
@NP	these	24117
@NP	six of eight animals	24142
@NP	six	24142
@NP	eight animals	24149
@NP	the OEC/ONF injections into the injured spinal cord	24164
@NP	the OEC/ONF injections	24164
@NP	the injured spinal cord	24192
@NP	a clearly blue Hoechst staining	24247
@NP	the putative injection areas rostral and caudal	24286
@NP	the injury site	24337
@NP	DPO112	24356
@NP	the OEC/ONF-biomatrix complex within the lesion gap	24376
@NP	the OEC/ONF-biomatrix complex	24376
@NP	the lesion gap	24413
@NP	prelabeled Hoechst-positive OEC/ONF	24453
@NP	a single transplanted animal	24493
@NP	a thin rim of Hoechst-positive cells	24523
@NP	a thin rim	24523
@NP	Hoechst-positive cells	24537
@NP	the OEC	24581
@NP	ONF-biomatrix complex and the host	24590
@NP	ONF-biomatrix complex	24590
@NP	the host	24616
@NP	spinal cord tissue	24625
@NP	The CS tract labeling	24645
@NP	all transplanted animals	24685
@NP	all control animals but one	24717
@NP	all control animals	24717
@NP	one	24741
@NP	analysis of CS tract regrowth	24753
@NP	analysis	24753
@NP	CS tract regrowth	24765
@NP	six transplanted and five control animals	24800
@NP	six transplanted	24800
@NP	five control animals	24821
@NP	saggital sections of these animals	24846
@NP	saggital sections	24846
@NP	these animals	24867
@NP	the BDA-labeled CS axons	24882
@NP	the border between the dorsal gray and white	24932
@NP	the border	24932
@NP	the dorsal gray and white	24951
@NP	the dorsal	24951
@NP	a distance of 2.5 -- 3 cm rostral from the injury site	24988
@NP	a distance of 2.5	24988
@NP	a distance	24988
@NP	2.5	25002
@NP	3 cm rostral from the injury site	25006
@NP	3 cm rostral	25006
@NP	the injury site	25024
@NP	the BDA-labeled CS axons	25041
@NP	an uninterrupted , unbranched course	25075
@NP	few instances innervating the underlying gray matter -LRB- Fig. 1A -RRB-	25115
@NP	few instances	25115
@NP	the underlying gray matter -LRB- Fig. 1A -RRB-	25141
@NP	the underlying gray matter	25141
@NP	Fig. 1A	25169
@NP	Closer to the injury site , these BDA-labeled CS axons	25179
@NP	the injury site , these BDA-labeled CS	25189
@NP	the injury site	25189
@NP	these BDA-labeled CS	25206
@NP	a strongly interrupted	25242
@NP	branched course	25266
@NP	apparent sprouting -LRB- Fig. 1B -RRB-	25288
@NP	apparent sprouting	25288
@NP	Fig. 1B	25308
@NP	all animals	25321
@NP	the majority of BDA-labeled CS axons	25334
@NP	the majority	25334
@NP	BDA-labeled CS axons	25350
@NP	the lesion site	25382
@NP	none	25437
@NP	the graft/lesion site	25447
@NP	only a small minority	25473
@NP	the graft/lesion site	25503
@NP	the caudal host tissue	25534
@NP	The effect	25558
@NP	the multifactorial transplantation intervention	25572
@NP	regrowth of injured BDA-labeled CS axons	25623
@NP	regrowth	25623
@NP	injured BDA-labeled CS axons	25635
@NP	four boxes in the saggital spinal cord sections -LRB- Fig. 1C -RRB-	25701
@NP	four boxes	25701
@NP	the saggital spinal cord sections -LRB- Fig. 1C -RRB-	25715
@NP	the saggital spinal cord sections	25715
@NP	Fig. 1C	25750
@NP	There	25760
@NP	a strong variation in the labeling efficiency of the CS tract	25770
@NP	a strong variation	25770
@NP	the labeling efficiency of the CS tract	25792
@NP	the labeling efficiency	25792
@NP	the CS tract	25819
@NP	the rostral reference	25836
@NP	the BDA immunoreactivity occupation	25859
@NP	10.1 % 6 5.5 % and 11.3 % 6 2.6 %	25899
@NP	10.1 % 6 5.5 % and 11.3 %	25899
@NP	transplanted and control animals , respectively -LRB- n.s. -RRB-	25932
@NP	transplanted	25932
@NP	control animals , respectively -LRB- n.s. -RRB-	25949
@NP	control animals , respectively	25949
@NP	control animals	25949
@NP	n.s.	25980
@NP	These values	25987
@NP	the 100 % value of labeled CS axons	26012
@NP	the 100 % value	26012
@NP	labeled CS axons	26030
@NP	rostral	26057
@NP	the injury site , the BDA immunoreactivity occupation in control animals	26068
@NP	the injury site	26068
@NP	the BDA immunoreactivity occupation in control animals	26085
@NP	the BDA immunoreactivity occupation	26085
@NP	control animals	26124
@NP	100 % to 33.2 % 6 6.0 % -LRB- Fig. 1D -RRB-	26165
@NP	100 % to 33.2 % 6 6.0 %	26165
@NP	100 % to 33.2 %	26165
@NP	6 6.0 %	26179
@NP	Fig. 1D	26187
@NP	animals	26206
@NP	the multifactorial transplantation at 4 weeks	26237
@NP	the multifactorial transplantation	26237
@NP	4 weeks	26275
@NP	injury	26289
@NP	a modest increase	26303
@NP	the BDA immunoreactivity occupation at this rostral location	26324
@NP	the BDA immunoreactivity occupation	26324
@NP	this rostral location	26363
@NP	100 % to 124.1 % 6 22.1 % -LRB- Fig. 1D -RRB-	26390
@NP	100 % to 124.1 % 6 22.1 %	26390
@NP	100 % to 124.1 %	26390
@NP	Fig. 1D	26414
@NP	Quantitative analysis	26424
@NP	a significant difference between BDA	26458
@NP	a significant difference	26458
@NP	BDA	26491
@NP	immunoreactivity occupation	26495
@NP	transplanted and control animals	26526
@NP	the lesion gap -LRB- two-tailed t-test , P < 0.01 -RRB-	26579
@NP	the lesion gap	26579
@NP	two-tailed t-test , P	26595
@NP	< 0.01	26616
@NP	<	26616
@NP	0.01	26618
@NP	The greatest BDA immunoreactivity	26625
@NP	the lesion/graft and caudal to the injury site	26667
@NP	the lesion/graft and caudal	26667
@NP	the injury site	26698
@NP	the two animal groups -LRB- n.s. -RRB-	26737
@NP	the two animal groups	26737
@NP	n.s.	26760
@NP	Further investigation of the CS axon regrowth response	26767
@NP	Further investigation	26767
@NP	the CS axon regrowth response	26792
@NP	the injured BDA-labeled CS axons	26834
@NP	the injury site	26887
@NP	the GAP43/B50	26919
@NP	protein -LRB- Fig. 1E -RRB-	26933
@NP	protein	26933
@NP	Fig. 1E	26942
@NP	The validity of the GAP43/B50 staining	26952
@NP	The validity	26952
@NP	the GAP43/B50 staining	26968
@NP	the observation of numerous GAP43-positive axons	27007
@NP	the observation	27007
@NP	numerous GAP43-positive axons	27026
@NP	the CST	27074
@NP	the OEC/ONF-biomatrix complex of transplanted animals -LRB- Fig. 1F -RRB-	27096
@NP	the OEC/ONF-biomatrix complex	27096
@NP	transplanted animals -LRB- Fig. 1F -RRB-	27129
@NP	transplanted animals	27129
@NP	Fig. 1F	27151
@NP	the behavioral analysis	27164
@NP	12 animals	27189
@NP	six that were successfully transplanted and six control animals	27215
@NP	six	27215
@NP	transplanted and six control animals	27242
@NP	transplanted	27242
@NP	six control animals	27259
@NP	Gross locomotor analysis using the BBB locomotor rating scale	27280
@NP	Gross locomotor analysis	27280
@NP	the BBB locomotor rating scale	27311
@NP	a significant drop	27349
@NP	the BBB score	27371
@NP	all animals at DPO1 -LRB- Fig. 2A -RRB-	27389
@NP	all animals	27389
@NP	DPO1 -LRB- Fig. 2A -RRB-	27404
@NP	DPO1	27404
@NP	Fig. 2A	27410
@NP	the first week	27427
@NP	the BBB score	27443
@NP	a plateau level of BBB score	27480
@NP	a plateau level	27480
@NP	BBB score	27499
@NP	11	27509
@NP	This score	27513
@NP	the day of transplantation -LRB- DPO28 -RRB-	27545
@NP	the day	27545
@NP	transplantation -LRB- DPO28 -RRB-	27556
@NP	transplantation	27556
@NP	DPO28	27573
@NP	Fine locomotor analysis , using the CatWalk gait analysis ,	27581
@NP	Fine locomotor analysis	27581
@NP	the CatWalk gait analysis	27612
@NP	very limited behavioral impairment	27646
@NP	a result of the SCI	27684
@NP	a result	27684
@NP	the SCI	27696
@NP	an increased base of support of the hind limbs -LRB- Fig. 3A -RRB-	27715
@NP	an increased base	27715
@NP	support of the hind limbs -LRB- Fig. 3A -RRB-	27736
@NP	support	27736
@NP	the hind limbs -LRB- Fig. 3A -RRB-	27747
@NP	the hind limbs	27747
@NP	Fig. 3A	27763
@NP	No impairments in fine locomotor parameters , such as swing speed ,	27773
@NP	No impairments	27773
@NP	fine locomotor parameters	27791
@NP	swing speed	27826
@NP	duration , or stride length of the hindlimbs ,	27845
@NP	duration	27845
@NP	stride length of the hindlimbs	27858
@NP	stride length	27858
@NP	the hindlimbs	27875
@NP	injury -LRB- Fig. 3B , C -RRB-	27910
@NP	injury	27910
@NP	Fig. 3B , C	27918
@NP	Fig. 3B	27918
@NP	C	27926
@NP	the second operation at DPO28 -LRB- transplantation or sham operation -RRB-	27948
@NP	the second operation	27948
@NP	DPO28 -LRB- transplantation or sham operation -RRB-	27972
@NP	DPO28	27972
@NP	transplantation or sham operation	27979
@NP	there	28015
@NP	a slight drop in the BBB score of both animal groups -LRB- Fig. 2A -RRB-	28025
@NP	a slight drop in the BBB score of	28025
@NP	a slight drop	28025
@NP	the BBB score of	28042
@NP	the BBB score	28042
@NP	animal groups -LRB- Fig. 2A -RRB-	28064
@NP	animal groups	28064
@NP	Fig. 2A	28079
@NP	the scores	28093
@NP	the pretransplantation plateau BBB level of 11	28125
@NP	the pretransplantation plateau BBB level	28125
@NP	11	28169
@NP	the entire postoperative period	28184
@NP	no significant differences	28217
@NP	OEC/ONF-transplanted and control animals	28266
@NP	Implementation	28308
@NP	the more sensitive and objective measure	28326
@NP	coordination , the regularity index -LRB- RI -RRB- ,	28371
@NP	coordination	28371
@NP	the regularity index -LRB- RI -RRB-	28385
@NP	the regularity index	28385
@NP	RI	28407
@NP	the BBB score	28417
@NP	intergroup differences	28449
@NP	the BBB score	28481
@NP	a similar extent in both the transplanted	28512
@NP	a similar extent	28512
@NP	the transplanted	28537
@NP	the control groups -LRB- Fig. 2B -RRB-	28558
@NP	the control groups	28558
@NP	Fig. 2B	28578
@NP	No signifi	28588
@NP	cant differences	28600
@NP	CatWalk locomotor parameters between OEC/ONF-transplanted and control animals	28634
@NP	CatWalk locomotor parameters	28634
@NP	OEC/ONF-transplanted and control animals	28671
@NP	stride length	28723
@NP	speed , and base of support of the hind limbs -LRB- Fig. 3A -- C -RRB-	28744
@NP	speed	28744
@NP	base of support of the hind limbs -LRB- Fig. 3A -- C -RRB-	28755
@NP	base	28755
@NP	support of the hind limbs -LRB- Fig. 3A -- C -RRB-	28763
@NP	support	28763
@NP	the hind limbs -LRB- Fig. 3A -- C -RRB-	28774
@NP	the hind limbs	28774
@NP	Fig. 3A -- C	28790
@NP	Fig. 3A	28790
@NP	C	28798
@NP	DISCUSSION	28803
@NP	this study	28817
@NP	we	28829
@NP	a multifactorial transplantation strategy	28837
@NP	clinically relevant large lesion gaps	28889
@NP	strategy	28932
@NP	1	28954
@NP	transplantation of aligned OEC	28957
@NP	transplantation	28957
@NP	aligned OEC	28976
@NP	ONF-biomatrix complexes	28989
@NP	2-mm-long dorsal hemisection lesion gaps	29018
@NP	2 -RRB- rostral and caudal OEC/ONF injections	29063
@NP	rostral	29066
@NP	caudal OEC/ONF injections	29078
@NP	This strategy	29105
@NP	4 weeks	29134
@NP	dorsal hemisection injury	29148
@NP	we	29183
@NP	the effects of the multifactorial transplantation strategy	29205
@NP	the effects	29205
@NP	the multifactorial transplantation strategy	29220
@NP	CS axon regrowth and functional recovery	29274
@NP	axon regrowth	29277
@NP	control animals	29316
@NP	possible damage	29372
@NP	opening of the lesion site and cellular injections	29401
@NP	opening	29401
@NP	the lesion site and cellular injections	29412
@NP	the lesion site	29412
@NP	cellular injections	29432
@NP	the second operation	29459
@NP	the lesion site	29481
@NP	control animals	29516
@NP	culture medium injections	29537
@NP	rostral and caudal	29575
@NP	the lesion site	29599
@NP	A majority of studies	29616
@NP	A majority	29616
@NP	studies	29630
@NP	promising effects of olfactory ensheathing glia	29652
@NP	promising effects	29652
@NP	olfactory ensheathing glia	29673
@NP	repair of injured CS axons	29703
@NP	repair	29703
@NP	injured CS axons	29713
@NP	small acute and chronic lesion gaps	29737
@NP	Li	29774
@NP	et al.	29777
@NP	1997 , 1998	29785
@NP	1997	29785
@NP	1998	29791
@NP	Ramon-Cueto et al. , 2000	29797
@NP	Ramon-Cueto	29797
@NP	et al. , 2000	29809
@NP	et al.	29809
@NP	2000	29817
@NP	Nash et al. , 2002	29823
@NP	Nash	29823
@NP	et al. , 2002	29828
@NP	et al.	29828
@NP	2002	29836
@NP	Keyvan-Fouladi et al.	29842
@NP	Keyvan-Fouladi	29842
@NP	et al.	29857
@NP	2003	29865
@NP	Our data	29872
@NP	the rather limited effects	29886
@NP	a multifactorial transplantation strategy	29916
@NP	olfactory ensheathing	29968
@NP	repair of chronically damaged CS axons	29993
@NP	repair	29993
@NP	chronically damaged CS axons	30003
@NP	large lesion gaps	30039
@NP	body functions	30066
@NP	It	30082
@NP	transplantation of mixed OEC/ONF cultures	30108
@NP	transplantation	30108
@NP	mixed OEC/ONF cultures	30127
@NP	regrowth	30161
@NP	injured CS axons	30173
@NP	small 8-week-old C1/C2 lesions	30197
@NP	the dorsal component of the CS tract	30241
@NP	the dorsal component	30241
@NP	the CS tract	30265
@NP	Keyvan	30292
@NP	Fouladi et al. , 2003	30300
@NP	Fouladi	30300
@NP	et al.	30308
@NP	2003	30316
@NP	these small lesions	30338
@NP	the regrowing CS axons	30359
@NP	the caudal host	30392
@NP	11 mm -LRB- Keyvan-Fouladi et al. , 2003 -RRB-	30427
@NP	11 mm	30427
@NP	Keyvan-Fouladi	30434
@NP	et al. , 2003	30449
@NP	et al.	30449
@NP	2003	30457
@NP	our study	30467
@NP	the majority of injured CS axons	30478
@NP	the majority	30478
@NP	injured CS axons	30494
@NP	the large thoracic injury site	30531
@NP	few injured CS axons	30573
@NP	the spinal gray matter	30625
@NP	the lesion site	30656
@NP	the caudal host tissue	30681
@NP	no differences	30709
@NP	OEC/ONF	30746
@NP	transplanted and control animals	30754
@NP	transplanted	30754
@NP	control animals	30771
@NP	There	30788
@NP	several issues	30801
@NP	the limited effects of our strategy on CS regrowth	30828
@NP	the limited effects	30828
@NP	our strategy on CS regrowth	30851
@NP	our strategy	30851
@NP	CS regrowth	30867
@NP	those of Keyvan-Fouladi and coworkers	30893
@NP	those	30893
@NP	Keyvan-Fouladi and coworkers	30902
@NP	Keyvan-Fouladi	30902
@NP	coworkers	30921
@NP	the level of the lesion	30939
@NP	the level	30939
@NP	the lesion	30952
@NP	our study vs. high-cervical in the study of Keyvan-Fouladi and coworkers	31011
@NP	our study	31011
@NP	high-cervical	31025
@NP	the study	31042
@NP	Keyvan-Fouladi and coworkers	31055
@NP	Keyvan-Fouladi	31055
@NP	coworkers	31074
@NP	It	31085
@NP	larger distances between the injured axon and the soma of the	31102
@NP	larger distances	31102
@NP	the injured axon and the soma of the	31127
@NP	the injured axon	31127
@NP	the soma of the	31148
@NP	the soma	31148
@NP	the	31160
@NP	neuron result	31175
@NP	a decreased regrowth capacity -LRB- Richardson et al. , 1984 -RRB-	31192
@NP	a decreased regrowth capacity	31192
@NP	Richardson	31223
@NP	et al. , 1984	31234
@NP	et al.	31234
@NP	1984	31242
@NP	the lesion size	31257
@NP	a role	31291
@NP	the study of Keyvan-Fouladi and coworkers	31302
@NP	the study	31302
@NP	Keyvan-Fouladi and coworkers	31315
@NP	Keyvan-Fouladi	31315
@NP	coworkers	31334
@NP	very small lesions	31345
@NP	these lesion gaps	31387
@NP	transplanted olfactory glia -LRB- Keyvan-Fouladi et al. , 2003 -RRB-	31431
@NP	transplanted olfactory glia	31431
@NP	Keyvan-Fouladi	31460
@NP	et al. , 2003	31475
@NP	et al.	31475
@NP	2003	31483
@NP	our study	31502
@NP	a rather large lesion gap	31513
@NP	that	31547
@NP	OEC/ONF	31577
@NP	biomatrix	31599
@NP	Regrowth of severed CS axons in such a large lesion site	31610
@NP	Regrowth	31610
@NP	CS axons	31630
@NP	a large lesion site	31647
@NP	Chuah et al. , 2004	31704
@NP	Chuah	31704
@NP	et al.	31710
@NP	2004	31718
@NP	Third	31725
@NP	the lack	31732
@NP	survival of transplanted OEC/ONF on the biomatrix within the lesion gap	31744
@NP	survival	31744
@NP	transplanted OEC/ONF on the biomatrix within the lesion gap	31756
@NP	transplanted OEC/ONF	31756
@NP	the biomatrix within the lesion gap	31780
@NP	the biomatrix	31780
@NP	the lesion gap	31801
@NP	the CS regrowth response	31847
@NP	Previous studies	31873
@NP	many types of growth-promoting cells	31906
@NP	many types	31906
@NP	growth-promoting cells	31920
@NP	olfactory ensheathing glia	31954
@NP	transplantation	31995
@NP	spinal injury sites	32016
@NP	Grill et al. , 1997 ; Boyd et al. , 2004 ; Joosten et al. , 2004	32037
@NP	Grill	32037
@NP	et al. , 1997 ; Boyd et al. , 2004 ; Joosten et al. , 2004	32043
@NP	et al. , 1997	32043
@NP	et al.	32043
@NP	1997	32051
@NP	Boyd et al. , 2004	32057
@NP	Boyd	32057
@NP	et al. , 2004	32062
@NP	et al.	32062
@NP	2004	32070
@NP	Joosten et al. , 2004	32076
@NP	Joosten	32076
@NP	et al. , 2004	32084
@NP	et al.	32084
@NP	2004	32092
@NP	these studies	32111
@NP	the transplanted cells	32126
@NP	transplanted cells	32130
@NP	the injured spinal cord environment	32184
@NP	these cells	32233
@NP	solid vehicle materials , such as collagen type I.	32250
@NP	solid vehicle materials	32250
@NP	collagen type I.	32283
@NP	contrast	32303
@NP	the OEC/ONF in our study	32313
@NP	the OEC/ONF	32313
@NP	our study	32328
@NP	the surface area of biodegradable poly -LRB- D , L -RRB- - lactide matrices ,	32357
@NP	the surface area of biodegradable poly -LRB- D , L -RRB-	32357
@NP	the surface area	32357
@NP	biodegradable poly -LRB- D , L -RRB-	32377
@NP	biodegradable poly	32377
@NP	lactide matrices	32401
@NP	these cells	32430
@NP	the many pathological processes	32454
@NP	the injured spinal cord environment	32499
@NP	biodegradation of poly -LRB- D , L -RRB- - lactide	32550
@NP	biodegradation	32550
@NP	poly -LRB- D , L -RRB- - lactide	32568
@NP	poly	32568
@NP	lactide	32578
@NP	a lowering	32600
@NP	the pH , which may be detrimental to the OEC/ONF cultured on the biomatrices	32614
@NP	the pH	32614
@NP	the OEC/ONF cultured on the biomatrices	32650
@NP	the OEC/ONF	32650
@NP	the biomatrices	32674
@NP	OEC/ONF	32708
@NP	transplantation rostral and caudal	32725
@NP	the lesion gap	32763
@NP	they	32779
@NP	Previous work	32813
@NP	the ability of transplanted OEC/ONF	32837
@NP	the ability	32837
@NP	transplanted OEC/ONF	32852
@NP	spinal cords	32891
@NP	small lesions -LRB- Li et al. , 1998 -RRB-	32909
@NP	small lesions	32909
@NP	Li	32924
@NP	et al. , 1998	32927
@NP	et al.	32927
@NP	1998	32935
@NP	it	32946
@NP	regrowing axons	32978
@NP	transplanted olfactory glia -LRB- Ramon-Cueto et al. , 2000 -RRB-	33027
@NP	transplanted olfactory glia	33027
@NP	Ramon-Cueto	33056
@NP	et al. , 2000	33068
@NP	et al.	33068
@NP	2000	33076
@NP	our study	33086
@NP	Hoechst	33097
@NP	the transplanted OEC/ONF	33126
@NP	Hoechst	33152
@NP	leak out	33172
@NP	leak	33172
@NP	transplanted cells	33195
@NP	neighboring host cells	33227
@NP	Iwashita	33251
@NP	et al. , 2000	33260
@NP	et al.	33260
@NP	2000	33268
@NP	Hoechst-positive cells	33289
@NP	a more extensive spinal cord area than that populated by transplanted cells	33331
@NP	a more extensive spinal cord area	33331
@NP	that populated by transplanted cells	33370
@NP	that	33370
@NP	transplanted cells	33388
@NP	our study	33420
@NP	the prelabeled transplanted OEC/ONF	33431
@NP	the injection area	33486
@NP	our knowledge	33509
@NP	prelabeling cells with Hoechst	33524
@NP	prelabeling cells	33524
@NP	Hoechst	33547
@NP	cell viability or the migratory activity of cells	33590
@NP	cell viability	33590
@NP	the migratory activity of cells	33608
@NP	the migratory activity	33608
@NP	cells	33634
@NP	we	33648
@NP	the injected OEC/ONF	33669
@NP	The lack of migration of injected OEC/ONF in our study	33707
@NP	The lack	33707
@NP	migration of injected OEC/ONF in our study	33719
@NP	migration	33719
@NP	injected OEC/ONF in our study	33732
@NP	injected OEC/ONF	33732
@NP	our study	33752
@NP	the putative higher concentrations	33780
@NP	cytotoxic substances	33818
@NP	pathological processes , such as hemorrhage and inflammation , in large lesions	33855
@NP	pathological processes , such as hemorrhage and inflammation ,	33855
@NP	pathological processes	33855
@NP	hemorrhage and inflammation	33887
@NP	large lesions	33919
@NP	small lesions	33947
@NP	a result	33965
@NP	the impaired migration	33977
@NP	injected OEC / ONF and the absence of any surviving transplanted OEC /	34003
@NP	injected OEC	34003
@NP	ONF and the absence of any surviving transplanted OEC	34017
@NP	ONF and the absence	34017
@NP	any surviving transplanted OEC	34040
@NP	any surviving	34040
@NP	OEC	34067
@NP	ONF on the biomatrices within the lesion gaps , no continuum of OEC/ONF	34072
@NP	ONF	34072
@NP	the biomatrices within the lesion gaps , no continuum of OEC/ONF	34079
@NP	the biomatrices	34079
@NP	the lesion gaps , no continuum of OEC/ONF	34102
@NP	the lesion gaps	34102
@NP	no continuum of OEC/ONF	34119
@NP	no continuum	34119
@NP	OEC/ONF	34135
@NP	the injured spinal cord	34157
@NP	The only positive effect	34182
@NP	our strategy on CS regrowth	34210
@NP	our strategy	34210
@NP	CS regrowth	34226
@NP	an enhanced presence of injured CS axons	34241
@NP	an enhanced presence	34241
@NP	injured CS axons	34265
@NP	the lesion gap	34302
@NP	the underlying mechanisms for this effect	34327
@NP	the underlying mechanisms	34327
@NP	this effect	34357
@NP	Fifth	34395
@NP	we	34402
@NP	a shorter time of delay in OEC/ONF transplantation	34425
@NP	a shorter time	34425
@NP	delay in OEC/ONF transplantation	34443
@NP	delay	34443
@NP	OEC/ONF transplantation	34452
@NP	more robust effects on CS regrowth	34499
@NP	more robust effects	34499
@NP	CS regrowth	34522
@NP	a delay of 4 weeks	34544
@NP	a delay	34544
@NP	4 weeks	34555
@NP	a chronic spinal cord injury in rodents -LRB- Houle and Tessler , 2003 -RRB-	34592
@NP	a chronic spinal cord injury	34592
@NP	rodents -LRB- Houle and Tessler , 2003 -RRB-	34624
@NP	rodents	34624
@NP	Houle and Tessler	34633
@NP	2003	34652
@NP	the 8-week-delayed OEC/ONF transplantation	34689
@NP	robust CS regrowth	34748
@NP	a small spinal lesion gap -LRB- Keyvan-Fouladi et al. , 2003 -RRB-	34774
@NP	a small spinal lesion gap	34774
@NP	Keyvan-Fouladi	34801
@NP	et al. , 2003	34816
@NP	et al.	34816
@NP	2003	34824
@NP	Injury to CS axons	34831
@NP	Injury	34831
@NP	CS axons	34841
@NP	a progressive die-back	34870
@NP	the majority	34906
@NP	these axons between 1	34922
@NP	these axons	34922
@NP	1	34942
@NP	2.5 mm rostral to the injury site at 8 -- 10 weeks after injury	34948
@NP	2.5 mm rostral to the injury site at 8	34948
@NP	2.5 mm rostral	34948
@NP	the injury site at 8	34966
@NP	the injury site	34966
@NP	8	34985
@NP	10 weeks after injury	34987
@NP	10 weeks	34987
@NP	injury	35002
@NP	Pallini et al. , 1988 ; von Meyenburg et al. , 1998 ; Oudega et al. , 1999	35010
@NP	Pallini	35010
@NP	et al. , 1988 ; von Meyenburg et al. , 1998 ; Oudega et al. , 1999	35018
@NP	et al. , 1988	35018
@NP	et al.	35018
@NP	1988	35026
@NP	von Meyenburg et al. , 1998	35032
@NP	von Meyenburg	35032
@NP	et al. , 1998	35046
@NP	et al.	35046
@NP	1998	35054
@NP	Oudega et al. , 1999	35060
@NP	Oudega	35060
@NP	et al. , 1999	35067
@NP	et al.	35067
@NP	1999	35075
@NP	Die-back of injured CS axons beyond 1 mm rostral to the injury site	35082
@NP	Die-back	35082
@NP	injured CS axons beyond 1 mm rostral to the injury site	35094
@NP	injured CS axons	35094
@NP	1 mm rostral to the injury site	35118
@NP	1 mm rostral	35118
@NP	the injury site	35134
@NP	more than 4 weeks	35170
@NP	OEC/ONF	35197
@NP	1 mm rostral to the lesion gap	35222
@NP	1 mm rostral	35222
@NP	the lesion gap	35238
@NP	4 weeks	35256
@NP	injury	35270
@NP	the transplanted OEC/ONF	35278
@NP	reach of the injured CS axons	35321
@NP	reach	35321
@NP	the injured CS axons	35330
@NP	Spontaneous sprouting responses of injured CS axons	35352
@NP	Spontaneous sprouting responses	35352
@NP	injured CS axons	35387
@NP	between 2 and 13 weeks	35410
@NP	injury -LRB- Li and Raisman , 1995 ; Hill et al. , 2001 -RRB-	35439
@NP	injury	35439
@NP	Li and Raisman , 1995 ; Hill et al. , 2001	35447
@NP	Li and Raisman	35447
@NP	1995 ; Hill et al.	35463
@NP	1995	35463
@NP	Hill et al.	35469
@NP	Hill	35469
@NP	et al.	35474
@NP	2001	35482
@NP	both spontaneous die-back and sprouting responses of injured CS axons	35496
@NP	both spontaneous die-back	35496
@NP	sprouting responses	35526
@NP	injured CS axons	35549
@NP	the rostrally injected OEC/ONF	35596
@NP	The interrupted and branched appearance of the injured CS axons	35628
@NP	The interrupted and branched appearance	35628
@NP	the injured CS axons	35671
@NP	the injury suggests that these axons displayed a strong sprouting response	35712
@NP	the injury	35712
@NP	these axons	35737
@NP	a strong	35759
@NP	response	35778
@NP	we	35797
@NP	GAP43/B50 , a growthassociated protein -LRB- Strittmatter et al. , 1992 -RRB- ,	35824
@NP	GAP43/B50	35824
@NP	a growthassociated protein -LRB- Strittmatter et al. , 1992 -RRB-	35835
@NP	a growthassociated protein	35835
@NP	Strittmatter	35863
@NP	et al. , 1992	35876
@NP	et al.	35876
@NP	1992	35884
@NP	these injured CS axons	35894
@NP	these	35894
@NP	CS axons	35908
@NP	it	35932
@NP	the OEC/ONF	35959
@NP	rostral to the lesion gap	35980
@NP	rostral	35980
@NP	the lesion gap	35991
@NP	an initial sprouting response	36014
@NP	injured CS axons	36047
@NP	12 weeks later	36078
@NP	the animals	36098
@NP	The transplanted prelabeled OEC/ONF	36127
@NP	rostral to the lesion gap	36172
@NP	rostral	36172
@NP	the lesion gap	36183
@NP	the injection areas	36226
@NP	1 mm rostral to the lesion gap	36249
@NP	1 mm rostral	36249
@NP	the lesion gap	36265
@NP	The injured CS axons	36281
@NP	the lesion gap	36323
@NP	its rostral edge	36352
@NP	the response of injured CS axons to OEC/ONF treatment	36377
@NP	the response	36377
@NP	injured CS axons to OEC/ONF treatment	36393
@NP	injured CS axons	36393
@NP	OEC/ONF treatment	36413
@NP	the release of diffusible neurotrophic factors	36461
@NP	the release	36461
@NP	diffusible neurotrophic factors	36476
@NP	the OEC / ONF	36511
@NP	the OEC	36511
@NP	ONF	36520
@NP	Neurotrophin-3 -LRB- NT-3 -RRB-	36525
@NP	Neurotrophin-3	36525
@NP	NT-3	36541
@NP	a putative diffusible neurotrophic factor	36550
@NP	this OEC/ONF effect	36602
@NP	NT-3 injection rostral	36634
@NP	a dorsal hemisection	36660
@NP	injury site	36681
@NP	a strong sprouting response of injured CS axons	36721
@NP	a strong sprouting response	36721
@NP	injured CS axons	36752
@NP	Schnell	36770
@NP	et al. , 1994	36778
@NP	et al.	36778
@NP	1994	36786
@NP	The expression of NT-3 by adult OEC	36793
@NP	The expression	36793
@NP	NT-3 by adult OEC	36811
@NP	NT-3	36811
@NP	adult OEC	36819
@NP	Ramon - Cueto and Avila , 1998	36853
@NP	Ramon	36853
@NP	Cueto and Avila , 1998	36860
@NP	Cueto and Avila	36860
@NP	1998	36877
@NP	The main focus of our study	36884
@NP	The main focus	36884
@NP	our study	36902
@NP	regrowth of the injured CS tract	36919
@NP	regrowth	36919
@NP	the injured CS tract	36931
@NP	we	36964
@NP	the effects of the transplantation strategy	37009
@NP	the effects	37009
@NP	the transplantation strategy	37024
@NP	the stride length	37056
@NP	the hind limbs	37077
@NP	the CS tract -LRB- Bregman et al. , 1995 ; Starkey et al. , 2005 -RRB-	37116
@NP	the CS tract	37116
@NP	Bregman	37130
@NP	et al. , 1995 ; Starkey et al. , 2005	37138
@NP	et al.	37138
@NP	1995 ; Starkey et al.	37146
@NP	1995	37146
@NP	Starkey et al.	37152
@NP	Starkey	37152
@NP	et al.	37160
@NP	2005	37168
@NP	the lowthoracic spinal cord of the rats in this study	37208
@NP	the lowthoracic spinal cord	37208
@NP	the rats in this study	37239
@NP	the rats	37239
@NP	this study	37251
@NP	the stride length of the hind limbs	37277
@NP	the stride length	37277
@NP	the hind limbs	37298
@NP	These results	37314
@NP	the relation between the CS tract and stride length of the hind limbs	37341
@NP	the relation	37341
@NP	the CS tract and stride length of the hind limbs	37362
@NP	the CS tract and stride length	37362
@NP	the hind limbs	37396
@NP	other axon tracts	37433
@NP	A locomotor parameter affected after dorsal hemisection	37452
@NP	A locomotor parameter	37452
@NP	dorsal hemisection	37489
@NP	the base of support of the hind limbs -LRB- Joosten et al. , 2004 -RRB-	37511
@NP	the base	37511
@NP	support of the hind limbs -LRB- Joosten et al. , 2004 -RRB-	37523
@NP	support	37523
@NP	the hind limbs -LRB- Joosten et al. , 2004 -RRB-	37534
@NP	the hind limbs	37534
@NP	Joosten	37550
@NP	et al. , 2004	37558
@NP	et al.	37558
@NP	2004	37566
@NP	no recovery	37588
@NP	this loco - motor parameter in OEC/ONF-transplanted vs. control animals	37613
@NP	this loco	37613
@NP	motor parameter in OEC/ONF-transplanted vs. control animals	37624
@NP	motor parameter	37624
@NP	OEC/ONF-transplanted vs. control animals	37643
@NP	OEC/ONF-transplanted	37643
@NP	control animals	37668
@NP	The relatively minor behavioral impairment after dorsal hemisection injury	37685
@NP	The relatively minor behavioral impairment	37685
@NP	dorsal hemisection injury	37734
@NP	further substantiated by the results on the BBB locomotor rating scale	37763
@NP	further	37763
@NP	the results on the BBB locomotor rating scale	37788
@NP	the results	37788
@NP	the BBB locomotor rating scale	37803
@NP	the CatWalk-related regularity index	37840
@NP	an objective and sensitive measure for coordination	37878
@NP	an objective and sensitive measure	37878
@NP	coordination	37917
@NP	the BBB score	37952
@NP	Koopmans et al. , 2005	37992
@NP	Koopmans	37992
@NP	et al.	38001
@NP	2005	38009
@NP	BBB scores	38016
@NP	15	38051
@NP	This	38055
@NP	the window for functional recovery after dorsal hemisection injury	38073
@NP	the window	38073
@NP	functional recovery after dorsal hemisection injury	38088
@NP	functional recovery	38088
@NP	dorsal hemisection injury	38114
@NP	only locomotor parameters	38165
@NP	paw rotation , toe clearance , and base of support of the hind limbs	38199
@NP	paw rotation	38199
@NP	toe clearance	38213
@NP	base of support of the hind limbs	38232
@NP	base	38232
@NP	support of the hind limbs	38240
@NP	support	38240
@NP	the hind limbs	38251
@NP	conclusion	38270
@NP	our multifactorial transplantation strategy	38282
@NP	regrowth of injured CS axons	38344
@NP	regrowth	38344
@NP	injured CS axons	38356
@NP	large lesion gaps	38380
@NP	OEC/ONF injections	38407
@NP	regrowth of injured CS axons	38448
@NP	regrowth	38448
@NP	injured CS axons	38460
@NP	small spinal lesion gaps	38484
@NP	it	38510
@NP	large lesion gaps	38535
@NP	small spinal lesion gaps	38576
@NP	Most axon-regrowth-promoting strategies	38602
@NP	animal models of SCI	38656
@NP	animal models	38656
@NP	SCI	38673
@NP	relatively small spinal lesion gaps	38682
@NP	spinal lesion gaps in humans	38727
@NP	spinal lesion gaps	38727
@NP	humans	38749
@NP	it	38780
@NP	strategies that stimulated axon regrowth across small lesion sites in animals	38812
@NP	strategies	38812
@NP	axon regrowth	38839
@NP	small lesion sites	38860
@NP	animals	38882
@NP	a clinical setting	38919
@NP	the large lesion gap	38950
@NP	we	38985
@NP	the dorsal hemisection lesion model	39002
@NP	regrowth of injured axons	39063
@NP	regrowth	39063
@NP	injured axons	39075
@NP	functional recovery	39131
@NP	the associated limited behavioral impairment	39163
@NP	Future studies	39209
@NP	optimization of the multifactorial transplantation strategy	39246
@NP	optimization	39246
@NP	the multifactorial transplantation strategy	39262
@NP	regrowth of injured CS axons	39319
@NP	regrowth	39319
@NP	injured CS axons	39331
@NP	large spinal lesion gaps	39355
@NP	ACKNOWLEDGMENTS The authors thank Dr.	39382
@NP	ACKNOWLEDGMENTS	39382
@NP	The authors	39398
@NP	Dr.	39416
@VP	Do Not Cross Large Spinal Lesion Gaps After a Multifactorial Transplantation	41
@VP	* G.C.	217
@VP	to stimulate regrowth of chronically injured CS axons	987
@VP	stimulate regrowth of chronically injured CS axons	990
@VP	caudal to the lesion site	1305
@VP	directly rostral to the lesion gap	1381
@VP	with no effects on injured CS axons at	1417
@VP	caudal to the lesion gap	1459
@VP	did not penetrate the OEC/ONFbiomatrix complex within the lesion gap	1515
@VP	penetrate the OEC/ONFbiomatrix complex within the lesion gap	1523
@VP	assessed with the BBB locomotor rating scale or Cat	1706
@VP	Walk gait analysis	1759
@VP	should be optimized to create an OEC/ONF continuum in the injured spinal cord	1840
@VP	be optimized to create an OEC/ONF continuum in the injured spinal cord	1847
@VP	optimized to create an OEC/ONF continuum in the injured spinal cord	1850
@VP	to create an OEC/ONF continuum in the injured spinal cord	1860
@VP	create an OEC/ONF continuum in the injured spinal cord	1863
@VP	thereby stimulate regrowth of injured CS axons across large spinal lesion gaps	1922
@VP	to stimulate regrowth of severed axons	2108
@VP	stimulate regrowth of severed axons	2111
@VP	to regrow	2454
@VP	regrow	2457
@VP	are induced -LRB- Dusart and Schwab , 1994 ; Tang et al. , 2003 -RRB-	2586
@VP	induced -LRB- Dusart and Schwab , 1994 ; Tang et al. , 2003 -RRB-	2590
@VP	initially up-regulate growth-associated genes	2854
@VP	advancing time	3001
@VP	called axonal die-back	3219
@VP	enhance the growth-promoting properties of the injured spinal cord environment	3315
@VP	to repair the injured spinal cord	3525
@VP	repair the injured spinal cord	3528
@VP	were used	3855
@VP	used	3860
@VP	is relatively unexplored	4171
@VP	may be promising in this respect for two reasons	4232
@VP	be promising in this respect for two reasons	4236
@VP	to use delayed OEC/ONF transplantation into 2-mm-long dorsal hemisection lesions	4636
@VP	use delayed OEC/ONF transplantation into 2-mm-long dorsal hemisection lesions	4639
@VP	to render a chronic spinal cord injury -LRB- Houle and Tessler , 2003 -RRB-	4796
@VP	render a chronic spinal cord injury -LRB- Houle and Tessler , 2003 -RRB-	4799
@VP	bridging large cavitations	4870
@VP	requires millions of OEC/ONF	4906
@VP	used an aligned OEC/ONF-biomatrix complex -LRB- Deumens et al. , 2004 -RRB-	4939
@VP	were made into the rostral and caudal host stumps	5173
@VP	made into the rostral and caudal host stumps	5178
@VP	stimulates regrowth of injured CS axons across large lesion gaps	5338
@VP	were interested in the effects of the complete multifactorial approach	5618
@VP	to control for the injection procedure	5767
@VP	control for the injection procedure	5770
@VP	were performed according to the recommendations of the European Commission	5871
@VP	performed according to the recommendations of the European Commission	5876
@VP	was made to minimize the number of animals and their suffering	6159
@VP	made to minimize the number of animals and their suffering	6163
@VP	to minimize the number of animals and their suffering	6168
@VP	minimize the number of animals and their suffering	6171
@VP	were subjected to a dorsal hemisection injury at T11/T12	6422
@VP	subjected to a dorsal hemisection injury at T11/T12	6427
@VP	were divided into two groups	6725
@VP	divided into two groups	6730
@VP	was treated according to a multifactorial transplantantion strategy	6784
@VP	treated according to a multifactorial transplantantion strategy	6788
@VP	served as the control group -LRB- see below -RRB-	6881
@VP	see below	6910
@VP	transplanting aligned OEC / ONF complexes into the lesion site	6965
@VP	aligned OEC / ONF complexes into the lesion site	6979
@VP	injecting OEC/ONF suspensions rostral and caudal to the lesion site	7031
@VP	using the above-mentioned locomotor tests ; at 9 weeks after transplantation	7174
@VP	was anterogradely traced by using biodextran amine -LRB- BDA -RRB-	7290
@VP	traced by using biodextran amine -LRB- BDA -RRB-	7308
@VP	using biodextran amine -LRB- BDA -RRB-	7318
@VP	were sacrificed , perfused , and used for histological analysis	7383
@VP	sacrificed , perfused , and used for histological analysis	7388
@VP	sacrificed	7388
@VP	perfused	7400
@VP	used for histological analysis	7414
@VP	were blind to the treatment	7532
@VP	described elsewhere -LRB- Ramon-Cueto and Nieto-Sampedro , 1992 -RRB-	7708
@VP	bred at the animal facilities of Maastricht University	7826
@VP	were decapitated	7882
@VP	decapitated	7887
@VP	diced into small fragments	8042
@VP	was stopped by addition of culture medium	8210
@VP	stopped by addition of culture medium	8214
@VP	supplemented with 10 %	8342
@VP	inactivated	8364
@VP	was washed twice with culture medium	8512
@VP	washed twice with culture medium	8516
@VP	was collected in 1 ml of culture medium	8553
@VP	collected in 1 ml of culture medium	8557
@VP	was achieved by mechanical trituration	8619
@VP	achieved by mechanical trituration	8623
@VP	are obtained by this procedure	8677
@VP	obtained by this procedure	8681
@VP	described previously	8765
@VP	were grown for 4	8979
@VP	grown for 4	8984
@VP	was refreshed	9052
@VP	refreshed	9056
@VP	was refreshed every 2 days	9098
@VP	refreshed every 2 days	9102
@VP	were used for transplantation into the spinal lesion site	9249
@VP	used for transplantation into the spinal lesion site	9254
@VP	was maintained in the Petri dishes and used for intraspinal OEC/ONF injections	9345
@VP	maintained in the Petri dishes and used for intraspinal OEC/ONF injections	9349
@VP	maintained in the Petri dishes	9349
@VP	used for intraspinal OEC/ONF injections	9384
@VP	was stopped by using culture medium	9614
@VP	stopped by using culture medium	9618
@VP	using culture medium	9629
@VP	was resuspended in culture medium	9706
@VP	resuspended in culture medium	9710
@VP	grown on these substrates for 4 days	9890
@VP	described previously	9989
@VP	were prelabeled with Hoechst	10143
@VP	prelabeled with Hoechst	10148
@VP	were extensively washed with culture medium	10357
@VP	washed with culture medium	10374
@VP	was applied to the eyes to prevent drying during the operation	10839
@VP	applied to the eyes to prevent drying during the operation	10843
@VP	to prevent drying during the operation	10863
@VP	prevent drying during the operation	10866
@VP	drying during the operation	10874
@VP	overlying the operation area	10949
@VP	was shaved	10978
@VP	shaved	10982
@VP	scrubbed with Betadine	11002
@VP	were sutured	11078
@VP	sutured	11083
@VP	were observed until awake and then returned to their home cages	11103
@VP	were observed until awake	11103
@VP	observed until awake	11108
@VP	then returned to their home cages	11133
@VP	received another i.p. injection with Temgesic	11217
@VP	was performed at T11/T12 of 16 animals	11306
@VP	performed at T11/T12 of 16 animals	11310
@VP	was exposed	11365
@VP	exposed	11369
@VP	was cut	11393
@VP	cut	11397
@VP	was incised at two spinal levels , 2 mm apart	11471
@VP	incised at two spinal levels , 2 mm apart	11475
@VP	using an aspiration device	11520
@VP	was removed	11604
@VP	removed	11608
@VP	was obtained by using the dorsal part of the CS tract as a reference	11662
@VP	obtained by using the dorsal part of the CS tract as a reference	11666
@VP	using the dorsal part of the CS tract as a reference	11678
@VP	is located in the ventralmost part of the dorsal funiculus	11752
@VP	become apparent in the center of the spinal cord	11896
@VP	was extended laterally	11969
@VP	extended laterally	11973
@VP	ascending dorsal column axons	12088
@VP	removing the connective tissue that massively invaded the lesion site	12243
@VP	invaded the lesion site	12289
@VP	was then covered with DuraFilm	12432
@VP	covered with DuraFilm	12441
@VP	to control for possible damage induced by the injection procedure	12808
@VP	control for possible damage induced by the injection procedure	12811
@VP	induced by the injection procedure	12839
@VP	labeling	12884
@VP	make burr holes on both sides of the cranium overlying the sensorimotor cortices	12921
@VP	overlying the sensorimotor cortices	12966
@VP	-LSB- 10 % in 0.1 M	13210
@VP	was left in place for 1 min and was then gradually withdrawn	13313
@VP	was left in place for 1 min	13313
@VP	left in place for 1 min	13317
@VP	was then gradually withdrawn	13345
@VP	withdrawn	13364
@VP	were removed and postfixed in cold 4 % buffered paraformaldehyde overnight	13643
@VP	removed and postfixed in cold 4 % buffered paraformaldehyde overnight	13648
@VP	buffered paraformaldehyde overnight	13681
@VP	was transferred to 10 % sucrose in PBS -LRB- 0.1 M , pH 7.6 -RRB-	13751
@VP	transferred to 10 % sucrose in PBS -LRB- 0.1 M , pH 7.6 -RRB-	13755
@VP	kept overnight at 48C	13809
@VP	were transferred to 25 % sucrose in PBS and kept for 3 days at 48C	13849
@VP	were transferred to 25 % sucrose in PBS	13849
@VP	transferred to 25 % sucrose in PBS	13854
@VP	kept for 3 days at 48C	13892
@VP	were frozen and stored at -- 808C	13987
@VP	frozen and stored at -- 808C	13992
@VP	frozen	13992
@VP	stored at -- 808C	14003
@VP	were serially cut -LRB- sagittal sections of 25 lm -RRB-	14060
@VP	cut -LRB- sagittal sections of 25 lm -RRB-	14074
@VP	were obtained per spinal cord	14140
@VP	obtained per spinal cord	14145
@VP	mounted on gelatin chrome-alumn -LRB- Sigma -RRB- - coated glass slides	14201
@VP	stored at -- 20 °C	14265
@VP	used	14537
@VP	were diluted in 0.3 % Triton X-100 in Tris-buffered saline -LRB- TBS-T -RRB-	14763
@VP	diluted in 0.3 % Triton X-100 in Tris-buffered saline -LRB- TBS-T -RRB-	14768
@VP	were overnight at room temperature	14859
@VP	were for 1.5 hr at room temperature	14925
@VP	were used in a mixture	15015
@VP	used in a mixture	15020
@VP	preceded the incubation with the Alexa-labeled secondary antibody	15106
@VP	washing steps	15319
@VP	involved 3 3 10 min in TBS	15333
@VP	was doubly stained for GFAP/BDA labeled CS axons or GAP43/BDA labeled CS axons	15381
@VP	stained for GFAP/BDA labeled CS axons or GAP43/BDA labeled CS axons	15392
@VP	labeled CS axons or GAP43/BDA labeled CS axons	15413
@VP	labeled CS axons	15443
@VP	were analyzed with an Olympus AX-70 microscope and epifluorescent illumination	15478
@VP	analyzed with an Olympus AX-70 microscope and epifluorescent illumination	15483
@VP	was equipped with a 320 objective and a 310 projection lens	15573
@VP	equipped with a 320 objective and a 310 projection lens	15577
@VP	was detected by using an MNG filter -LRB- Chroma Technology Corp. -RRB-	15793
@VP	detected by using an MNG filter -LRB- Chroma Technology Corp. -RRB-	15797
@VP	using an MNG filter -LRB- Chroma Technology Corp. -RRB-	15809
@VP	was detected by using a U-MNIBA filter -LRB- Chroma Technology Corp. -RRB-	15890
@VP	detected by using a U-MNIBA filter -LRB- Chroma Technology Corp. -RRB-	15894
@VP	using a U-MNIBA filter -LRB- Chroma Technology Corp. -RRB-	15906
@VP	cooled CCD camera -LRB- Paes , Zoeterwoude , The Netherlands -RRB-	16092
@VP	were analyzed with the image analyzing system analySIS 3.0	16161
@VP	analyzed with the image analyzing system analySIS 3.0	16166
@VP	analyzing system analySIS 3.0	16190
@VP	were analyzed	16336
@VP	analyzed	16341
@VP	were placed at four different locations in the spinal cord sections	16396
@VP	placed at four different locations in the spinal cord sections	16401
@VP	will be termed the rostral reference	16567
@VP	be termed the rostral reference	16572
@VP	termed the rostral reference	16575
@VP	was placed in the dorsal gray/white matter directly rostral to the injury site	16620
@VP	placed in the dorsal gray/white matter directly rostral to the injury site	16624
@VP	was placed in the gray matter beneath the lesion site	16714
@VP	placed in the gray matter beneath the lesion site	16718
@VP	were present underneath the lesion site	16792
@VP	was placed in the area where most BDA immunoreactivity was found	16841
@VP	placed in the area where most BDA immunoreactivity was found	16845
@VP	was found	16896
@VP	found	16900
@VP	could be found	17033
@VP	be found	17039
@VP	found	17042
@VP	were analyzed in all the sections containing BDA-labeled CS axons	17209
@VP	analyzed in all the sections containing BDA-labeled CS axons	17214
@VP	containing BDA-labeled CS axons	17243
@VP	was measured	17378
@VP	measured	17382
@VP	were summed	17431
@VP	summed	17436
@VP	tracing	17483
@VP	was highly variable among animals	17491
@VP	was taken as the 100 % reference value of BDA-labeled axons of each animal	17576
@VP	taken as the 100 % reference value of BDA-labeled axons of each animal	17580
@VP	were expressed relative to that of the rostral reference	17704
@VP	expressed relative to that of the rostral reference	17709
@VP	has been described previously by others -LRB- Goldshmit et al. , 2004 -RRB-	17794
@VP	been described previously by others -LRB- Goldshmit et al. , 2004 -RRB-	17798
@VP	described previously by others -LRB- Goldshmit et al. , 2004 -RRB-	17803
@VP	Testing Basso Beattie Bresnahan -LRB- BBB -RRB- locomotor rating scale	17871
@VP	ranges from 0 to 21	18039
@VP	were averaged and taken as the BBB score of the animal	18125
@VP	averaged and taken as the BBB score of the animal	18130
@VP	can be found elsewhere -LRB- Hamers et al. , 2001 ; Koopmans et al. , 2005 -RRB-	18584
@VP	be found elsewhere -LRB- Hamers et al. , 2001 ; Koopmans et al. , 2005 -RRB-	18588
@VP	found elsewhere -LRB- Hamers et al. , 2001 ; Koopmans et al. , 2005 -RRB-	18591
@VP	was used for animals to cross a glass runway without hesitation	18691
@VP	used for animals to cross a glass runway without hesitation	18695
@VP	to cross a glass runway without hesitation	18712
@VP	cross a glass runway without hesitation	18715
@VP	were motivated via a 12 g/day food-restriction protocol	18797
@VP	motivated via a 12 g/day food-restriction protocol	18802
@VP	were deprived of food	18905
@VP	deprived of food	18910
@VP	pellets PJPPP-0045 ; Sandown Chemical Ltd. , Hampton , United Kingdom	18964
@VP	were used as a reward	19071
@VP	used as a reward	19076
@VP	were used	19133
@VP	used	19138
@VP	is an extremely important aspect in the BBB score	19200
@VP	is rather subjective	19331
@VP	requires correct assessment of coordination	19397
@VP	obtained from the CatWalk analysis	19571
@VP	is implemented in the BBB scoring -LRB- Koopmans et al. , 2005 -RRB-	19606
@VP	implemented in the BBB scoring -LRB- Koopmans et al. , 2005 -RRB-	19609
@VP	multiplied by four	19763
@VP	divided by the total number of paw placements	19783
@VP	multiplied by 100 %	19833
@VP	are considered coordinated	19901
@VP	considered coordinated	19905
@VP	coordinated	19916
@VP	are coordinated	19977
@VP	coordinated	19981
@VP	implemented into the BBB score of the animal at that testing day , respectively	20055
@VP	injured by a low-thoracic dorsal hemisection injury	20254
@VP	were labeled with the anterograde tracer BDA	20307
@VP	labeled with the anterograde tracer BDA	20312
@VP	using four boxes as indicated in C	20552
@VP	indicated with arrowheads	20750
@VP	were not GAP43/B50 immunoreactive -LRB- BDA in red , GAP43/B50 in green -RRB-	20777
@VP	note the GAP43/B50 immunoreactive fiber -LRB- arrow -RRB-	20845
@VP	was innervated by GAP43/B50-immunoreactive fibers -LRB- F -RRB-	20951
@VP	innervated by GAP43/B50-immunoreactive fibers -LRB- F -RRB-	20955
@VP	were evaluated by using the BBB locomotor rating scale	21160
@VP	evaluated by using the BBB locomotor rating scale	21165
@VP	using the BBB locomotor rating scale	21178
@VP	remained at this postoperative plateau	21474
@VP	increased the BBB scores	21599
@VP	were detected	21666
@VP	detected	21671
@VP	Dashed line	21681
@VP	represents	21693
@VP	reflecting fine locomotor functions as assessed with the CatWalk gait analysis	21865
@VP	assessed with the CatWalk gait analysis	21904
@VP	are indicated	21944
@VP	indicated	21948
@VP	increased after SCI -LRB- A -RRB-	22003
@VP	did not result in any recovery of this parameter	22057
@VP	result in any recovery of this parameter	22065
@VP	remained unaffected by the SCI	22166
@VP	Dashed line	22198
@VP	represents the time of transplantation	22210
@VP	showed a significant drop in the BBB score at postoperative time points	22294
@VP	was 11 at DPO28 -LRB- the day of transplantation -RRB-	22396
@VP	was in line with previous work -LRB- Joosten et al. , 2004 -RRB-	22447
@VP	are useful for the CatWalk analysis at DPO28	22616
@VP	making them unsuitable	22898
@VP	were therefore excluded from the study	22947
@VP	therefore excluded from the study	22952
@VP	could be detected -LRB- see below -RRB-	23057
@VP	be detected -LRB- see below -RRB-	23063
@VP	detected -LRB- see below -RRB-	23066
@VP	see below	23076
@VP	were excluded from the study	23114
@VP	excluded from the study	23119
@VP	consisted of eight animals ; the control group of six	23174
@VP	developed by Ramon-Cueto and coworkers -LRB- 1992 -RRB-	23291
@VP	elongated	23519
@VP	flattened	23727
@VP	left in Petri dishes	23951
@VP	was completely devoid of prelabeled Hoechst-positive OEC/ONF	24428
@VP	detected between the OEC / ONF-biomatrix complex and the host spinal cord tissue	24564
@VP	was successful in all transplanted animals and in all control animals but one	24667
@VP	was performed in six transplanted and five control animals	24783
@VP	performed in six transplanted and five control animals	24787
@VP	were clearly observed at the border between the dorsal gray and white matter	24907
@VP	observed at the border between the dorsal gray and white matter	24920
@VP	innervating the underlying gray matter -LRB- Fig. 1A -RRB-	25129
@VP	stopped at the lesion site	25371
@VP	did not grow any farther caudally	25402
@VP	grow any farther caudally	25410
@VP	none into the graft/lesion site	25437
@VP	using four boxes in the saggital spinal cord sections -LRB- Fig. 1C -RRB-	25695
@VP	was a strong variation in the labeling efficiency of the CS tract	25766
@VP	were set as the 100 % value of labeled CS axons	26000
@VP	set as the 100 % value of labeled CS axons	26005
@VP	was clearly reduced from 100 % to 33.2 % 6 6.0 % -LRB- Fig. 1D -RRB-	26140
@VP	reduced from 100 % to 33.2 % 6 6.0 % -LRB- Fig. 1D -RRB-	26152
@VP	were subjected to the multifactorial transplantation at 4 weeks after injury	26219
@VP	subjected to the multifactorial transplantation at 4 weeks after injury	26224
@VP	directly rostral to the lesion gap -LRB- two-tailed t-test , P < 0.01 -RRB-	26559
@VP	did not differ between the two animal groups -LRB- n.s. -RRB-	26714
@VP	differ between the two animal groups -LRB- n.s. -RRB-	26722
@VP	showed that the injured BDA-labeled CS axons directly rostral to the injury site	26822
@VP	rostral to the injury site	26876
@VP	did not express the GAP43/B50	26903
@VP	express the GAP43/B50	26911
@VP	belonging to the CST	27061
@VP	were included , six that were successfully transplanted and six control animals	27200
@VP	included , six that were successfully transplanted and six control animals	27205
@VP	were successfully transplanted and six control animals	27224
@VP	using the BBB locomotor rating scale	27305
@VP	increased to a plateau level of BBB score 11	27467
@VP	was maintained until the day of transplantation -LRB- DPO28 -RRB-	27524
@VP	maintained until the day of transplantation -LRB- DPO28 -RRB-	27528
@VP	using the CatWalk gait analysis	27606
@VP	were detected after injury -LRB- Fig. 3B , C -RRB-	27890
@VP	detected after injury -LRB- Fig. 3B , C -RRB-	27895
@VP	was a slight drop in the BBB score of both animal groups -LRB- Fig. 2A -RRB-	28021
@VP	recovered to the pretransplantation plateau BBB level of 11	28112
@VP	were observed between OEC/ONF-transplanted and control animals	28244
@VP	observed between OEC/ONF-transplanted and control animals	28249
@VP	swing	28738
@VP	to repair clinically relevant large lesion gaps	28879
@VP	repair clinically relevant large lesion gaps	28882
@VP	consisted of 1	28941
@VP	was applied at 4 weeks after dorsal hemisection injury	29119
@VP	applied at 4 weeks after dorsal hemisection injury	29123
@VP	were untreated	29332
@VP	was also opened in control animals	29497
@VP	opened in control animals	29506
@VP	were placed rostral and caudal from the lesion site	29563
@VP	placed rostral and caudal from the lesion site	29568
@VP	involving olfactory ensheathing on repair of chronically damaged CS axons	29958
@VP	lost body functions	30061
@VP	interrupting the dorsal component of the CS tract unilaterally	30228
@VP	crossing these small lesions	30329
@VP	remained rostral to the large thoracic injury site	30511
@VP	were observed between OEC/ONF transplanted and control animals	30724
@VP	observed between OEC/ONF transplanted and control animals	30729
@VP	involved	30979
@VP	might have played a role	31273
@VP	have played a role	31279
@VP	played a role	31284
@VP	had to be crossed	31364
@VP	to be crossed	31368
@VP	be crossed	31371
@VP	crossed	31374
@VP	existed that was filled not only with OEC/ONF but also with biomatrix	31539
@VP	was filled not only with OEC/ONF but also with biomatrix	31552
@VP	filled not only with OEC/ONF but also with biomatrix	31556
@VP	severed CS axons in such a large lesion site	31622
@VP	has been shown to be more difficult -LRB- Chuah et al. , 2004 -RRB-	31667
@VP	been shown to be more difficult -LRB- Chuah et al. , 2004 -RRB-	31671
@VP	shown to be more difficult -LRB- Chuah et al. , 2004 -RRB-	31676
@VP	to be more difficult -LRB- Chuah et al. , 2004 -RRB-	31682
@VP	be more difficult -LRB- Chuah et al. , 2004 -RRB-	31685
@VP	might have strongly influenced the CS regrowth response	31816
@VP	have strongly influenced the CS regrowth response	31822
@VP	strongly influenced the CS regrowth response	31827
@VP	embedding these cells into solid vehicle materials , such as collagen type I.	32223
@VP	occurring in the injured spinal cord environment	32486
@VP	may be detrimental to the OEC/ONF cultured on the biomatrices	32628
@VP	be detrimental to the OEC/ONF cultured on the biomatrices	32632
@VP	cultured on the biomatrices	32662
@VP	survived transplantation rostral and caudal to the lesion gap	32716
@VP	did not extensively migrate	32784
@VP	migrate	32804
@VP	to migrate within spinal cords with small lesions -LRB- Li et al. , 1998 -RRB-	32873
@VP	migrate within spinal cords with small lesions -LRB- Li et al. , 1998 -RRB-	32876
@VP	associated transplanted olfactory glia -LRB- Ramon-Cueto et al. , 2000 -RRB-	33016
@VP	was used to prelabel the transplanted OEC/ONF	33105
@VP	used to prelabel the transplanted OEC/ONF	33109
@VP	to prelabel the transplanted OEC/ONF	33114
@VP	prelabel the transplanted OEC/ONF	33117
@VP	prelabeled transplanted cells and staining neighboring host cells	33184
@VP	prelabeled transplanted cells	33184
@VP	staining neighboring host cells	33218
@VP	populated by transplanted cells	33375
@VP	were restricted to the injection area	33467
@VP	been described to affect cell viability or the migratory activity of cells	33565
@VP	described to affect cell viability or the migratory activity of cells	33570
@VP	to affect cell viability or the migratory activity of cells	33580
@VP	affect cell viability or the migratory activity of cells	33583
@VP	can conclude that the injected OEC/ONF did not migrate	33651
@VP	conclude that the injected OEC/ONF did not migrate	33655
@VP	did not migrate	33690
@VP	migrate	33698
@VP	transplanted OEC	34054
@VP	was formed in the injured spinal cord	34143
@VP	formed in the injured spinal cord	34147
@VP	is an enhanced presence of injured CS axons	34238
@VP	remain to be established	34369
@VP	to be established	34376
@VP	be established	34379
@VP	established	34382
@VP	could have resulted in more robust effects on CS regrowth	34476
@VP	have resulted in more robust effects on CS regrowth	34482
@VP	resulted in more robust effects on CS regrowth	34487
@VP	takes more than 4 weeks	35164
@VP	were injected at 1 mm rostral to the lesion gap at 4 weeks after injury	35205
@VP	injected at 1 mm rostral to the lesion gap at 4 weeks after injury	35210
@VP	were still within reach of the injured CS axons	35303
@VP	might have been influenced by the rostrally injected OEC/ONF	35566
@VP	have been influenced by the rostrally injected OEC/ONF	35572
@VP	been influenced by the rostrally injected OEC/ONF	35577
@VP	influenced by the rostrally injected OEC/ONF	35582
@VP	suggests that these axons displayed a strong sprouting response	35723
@VP	displayed a strong sprouting response	35749
@VP	sprouting response	35768
@VP	injured CS axons	35900
@VP	subsided 12 weeks later when the animals were sacrificed	36069
@VP	were sacrificed	36110
@VP	sacrificed	36115
@VP	approached the lesion gap completely to its rostral edge	36312
@VP	mediated by the release of diffusible neurotrophic factors by the OEC / ONF	36449
@VP	has been shown to stimulate a strong sprouting response of injured CS axons	36693
@VP	been shown to stimulate a strong sprouting response of injured CS axons	36697
@VP	shown to stimulate a strong sprouting response of injured CS axons	36702
@VP	to stimulate a strong sprouting response of injured CS axons	36708
@VP	stimulate a strong sprouting response of injured CS axons	36711
@VP	has also been proposed -LRB- Ramon - Cueto and Avila , 1998 -RRB-	36829
@VP	been proposed -LRB- Ramon - Cueto and Avila , 1998 -RRB-	36838
@VP	proposed -LRB- Ramon - Cueto and Avila , 1998 -RRB-	36843
@VP	was on regrowth of the injured CS tract	36912
@VP	linked to the CS tract -LRB- Bregman et al. , 1995 ; Starkey et al. , 2005 -RRB-	37106
@VP	dorsally hemisectioning the lowthoracic spinal cord of the rats in this study	37184
@VP	did not affect the stride length of the hind limbs	37262
@VP	affect the stride length of the hind limbs	37270
@VP	is not independent of other axon tracts	37411
@VP	affected after dorsal hemisection	37474
@VP	is the base of support of the hind limbs -LRB- Joosten et al. , 2004 -RRB-	37508
@VP	noted at this loco - motor parameter in OEC/ONF-transplanted vs. control animals	37604
@VP	is further substantiated by the results on the BBB locomotor rating scale	37760
@VP	substantiated by the results on the BBB locomotor rating scale	37771
@VP	implemented into the BBB score	37935
@VP	validated previously -LRB- Koopmans et al. , 2005 -RRB-	37970
@VP	were increased to about 15	38027
@VP	increased to about 15	38032
@VP	to	38042
@VP	did not stimulate regrowth of injured CS axons across large lesion gaps	38326
@VP	stimulate regrowth of injured CS axons across large lesion gaps	38334
@VP	concluded that large lesion gaps differ completely from small spinal lesion gaps	38520
@VP	differ completely from small spinal lesion gaps	38553
@VP	are tested in animal models of SCI with relatively small spinal lesion gaps	38642
@VP	tested in animal models of SCI with relatively small spinal lesion gaps	38646
@VP	can be relatively long	38756
@VP	be relatively long	38760
@VP	stimulated axon regrowth across small lesion sites in animals	38828
@VP	be as effective in a clinical setting , because of the large lesion gap	38900
@VP	is suitable for studying regrowth of injured axons	39038
@VP	studying regrowth of injured axons	39054
@VP	is relatively unsuitable for studying functional recovery	39093
@VP	studying functional recovery	39122
@VP	to stimulate regrowth of injured CS axons across large spinal lesion gaps	39306
@VP	stimulate regrowth of injured CS axons across large spinal lesion gaps	39309
@VP	thank Dr.	39410
